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ABSTRACT 
MEAN PLATELET VOLUME AN INDICATOR OF ASCITIC FLUID 
INFECTIONS IN CIRRHOTIC PATIENTS 
AIM 
Ascitic fluid infection primarily consists of two variants- Spontaneous Bacterial 
peritonitis and culture negative neutrocytic ascites. Mean platelet volume 
(MPV) is used as a cheap and non invasive indicator of inflammation in various 
systemic conditions. So our aim is to analyse whether platelet size alteration 
would be used as an indicator of ascetic fluid infection in cirrhotic patients. 
MATERIALS AND METHODS 
 A total of 75 patients with ascites with cirrhosis were enrolled in this study. 
According to ascitic fluid analysis, 29 patients were diagnosed to have ascetic 
fluid infection. CBC including MPV, ESR were determined for all participants. 
The ability of MPV in determining ascetic fluid infections were analysed using 
Pearson chi- square and  Fisher extract test. 
RESULTS 
A statistically significant increase in MPV was observed in cirrhotic patients 
with AFI compared to cirrhotic patients without AFI (P<0.005). A statistically 
significant observation was observed in respect to MPV, ESR, TC, Ascitic fluid 
PMN count and culture. 
CONCLUSION 
Our study shows that MPV is increased in cirrhotic patients with AFI. MPV 
measurement can be considered as an accurate diagnostic test in predicting AFI, 
possibly due to ongoing systemic inflammatory response. 
KEY WORDS: Ascitic fluid infection, Spontaneous bacterial peritonitis, Mean 
platelet volume, Cirrhosis, Inflammation. 
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INTRODUCTION 
Ascites is a Greek derivative (askos) and it refers to bag or sack. Ascites 
is pathologic fluid accumulation within the peritoneal cavity. The most common 
cause of ascites is cirrhosis with portal hypertension (85%) which occurs within 
10years of diagnosing cirrhosis. 
Ascites is due to many factors like diseases involving peritoneum  
(peritonitis, malignancy), liver disease, cardiac failure, hypoproteinemia. In 
Western countries, cirrhosis is the most common cause of ascites(76%), 
followed by peritoneal malignancy(14%), cardiac failure(5%), peritoneal 
tuberculosis(4%) 
The development of ascites in cirrhotic patients denotes that the patient 
progressed to decompensated cirrhosis. There are many complications of 
cirrhosis like portal hypertension, hepatic encephalopathy, hepatorenal 
syndrome of which the development of portal hypertension and its manifestation 
ascites is common and is gaining more importance.  
Cirrhosis is a linguistic disorder with indolent course and many patients   
will be asymptomatic until decompensation. Early and well - compensated 
cirrhosis usually present as loss of appetite and weight loss, malaise, fatigue and 
weakness. Decompensated Liver Disease is an end stage liver disorder with 
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liver fibrosis and with complications like ascites, variceal bleeding, hepatic 
encephalopathy, SBP and hepatorenal syndrome. 
DCLD have poor prognosis with 1 year and 5 year mortality rates of 56% 
and 80% respectively. 
Cirrhosis is an immunocompromised status where both humoral and cell 
mediated immunity are decreased. So these patients have reduced bactericidal 
opsonin activity, reduced complements (C3, C4), protein C and fibronectin. The 
local immune function is also decreased. Due to portosystemic shunting, 
bacteria and its endotoxins from portal circulation are not cleared by cirrhotic 
liver. This predisposes the patient to lots of infection. Bacterial infections takes 
about 37-57% of death in DCLD patients. Nosocomial infections takes about 
30-32% and upto 42% of death with variceal bleed. The most common bacterial 
infections in descending order are spontaneous bacterial peritonitis (15-30%), 
urinary tract infections (25-29%), pneumonia (18-22%), bacteremia(17%), and 
soft tissue infections(15%). 
In Gastrointestinal variceal bleeding there is disruption of mucosal barrier 
integrity during bleeding and during invasive procedures. So GIT bleeding is 
associated with infections in 60% of patients. 
Infections trigger cytokine pathway with release of various inflammatory 
markers and vasoactive mediators that causes increased variceal pressure, 
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distorted homeostasis leading to further bleeding. So failure to control variceal 
bleeding within 120 hours are associated with increased rebleeding rates. So 
early antibiotic prophylaxis prevents infection and episodes of rebleeding and 
also reduces the need of blood transfusion. The recurrence rate after first 
episode of SBP are 41% at 5 months, 63% at one year and 72% at 2 years. Early 
and sensible prophylaxis reduces recurrent rate by 25%. The frequency of 
ascitic fluid infection among out patient is as low as 0-3.7%. The in- patient 
mortality varies from 22-45% and mortality rate at one year follow up varies 
from 57-72%. 
AFIs are under diagnosed by conventional culture methods since the 
Median bacterial concentration is only about one to two organisms per millilitre. 
Hence this study is done to detect Ascitic Fluid Infections (AFI)  in out 
patients and in patients with Decompensated Chronic Liver Disease (DCLD) by 
blood Mean Platelet Volume (MPV) test. With this we can diagnose ascitic fluid 
infection at the earliest and treating the patients with appropriate antibiotics at 
the earliest thereby preventing further complications. 
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                                AIMS AND OBJECTIVES 
1. The usefulness of Blood Mean Platelet Volume in the rapid and early 
diagnosis of spontaneous bacterial peritonitis in Decompensated Chronic 
Liver Disease with ascites, so that rapid diagnosis of ascitic fluid 
infection in cirrhotic patient and starting early antibiotics to reduce the 
morbidity and mortality of the disease which can be established. 
2. To study the incidence and prevalence of Ascitic Fluid Infection in 
cirrhotic patients of different etiologies. 
3. To study the prevalence of ascitic fluid infection among in patients  with 
DCLD. 
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REVIEW OF LITERATURE 
CIRRHOSIS 
Cirrhosis means non remitting, progressive, diffuse fibrosis followed by 
nodular regeneration of liver so that the liver architecture is altered. Long 
standing injury  proceed to progressive injury to the liver resulting in cirrhosis. 
Persistent wound healing resulting in fibrosis. For clinical manifestation to 
occur, atleast 80-90% of liver parenchyma  should be destroyed. Cirrhosis is an 
indolent disease with silent course and the patient remain asymptomatic until 
they reach the stage of decomposition.  
CAUSES OF CIRRHOSIS 
1. Alcoholism 
2. Cardiac cirrhosis 
3. Viral induced-Hepatitis B&C 
4. Autoimmune hepatitis 
5. Non alcoholic  steatohepatitis 
6. Biliary cirrhosis 
i. Primary biliary cirrhosis 
ii. Primary sclerosing cholangitis 
iii. Autoimmune cholangiopathy 
7. Chronic viral hepatitis 
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8. Inherited metabolic liver diseases 
i. Haemochromatosis 
ii. Wilson disease 
iii. Cystic fibrosis 
iv. α 1 antitrypsin deficiency 
9. Cyptogenic cirrhosis 
 
ALCOHOLIC LIVER DISEASE 
Alcoholic Liver Disease(ALD) is the most important risk factor for the 
development of cirrhosis.  Individuals who consume large quantity of alcohol 
for prolonged period, about 60-80gm/day in males and >20gm/day in females 
over 10 years or longer progress to steatosis of liver in 92% of people. Steatosis 
can progress to alcoholic hepatitis in 12-37% of people and to cirrhosis in 5-
18% of people. 
Women are more prone to develop Alcoholic liver disease in a short 
lifespan due to decreased activity of alcohol dehydrogenase in gastric mucosa 
and in the liver. Also women have a lean body mass and low threshold for toxic 
dose when compared to men. This has been attributed to the gender dependent 
differences in the hepatic metabolism of alcohol. 
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COMPLICATIONS OF CIRRHOSIS   
1. Portal hypertension 
i. Gastro esophageal  varices 
ii. Portal hypertensive gastropathy 
iii. Splenomegaly 
iv. Ascites 
v. Spontaneous bacterial peritonitis 
2. Hepato renal syndrome 
3. Hepato pulmonary syndrome 
4. Hepatic encephalopathy 
5. Porto pulmonary hypertension 
6. Malnutrition 
7. Coagulopathies 
8. Bone disease 
9. Haematological abnormalities 
i. Anaemia  
ii. Hemolysis 
iii. Neutropenia 
iv. Thombocytopenia 
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ASCITES 
Defined as pathological accumulation of fluid in the peritoneal cavity. The 
most recent theory for the formation of ascitic fluid  is “The peripheral 
arterial vasodilation hypothesis”. The older theories are Underfilling and 
overfilling theory. 
PATHOGENESIS OF ASCITES 
In cirrhotic patients the changes in portal flow and resistance are due to 
mechanical and vascular factors. 
 Mechanical factors include the fibrosis and nodularity with distortion of 
the vascular architecture and the remodelling of the cirrhotic liver.  
 Vascular factors include intrahepatic vasoconstriction, due to increased 
production of vasoconstrictors like Endothelin-1 which contributes to 
increased intrahepatic resistance. Both these leads to  PORTAL 
(SINUSOIDAL) HYPERTENSION.   
This portal hypertension activates vasodilatory mechanisms. There is increased 
production of nitric oxide (NO) in the splanchnic circulation which leads to 
splanchnic and peripheral arterial vasodilation. The later causes decreased 
levelling of systemic  vasculature and produces drop in systemic pressure. 
The fall in systemic pressure causes   baroreceptor- induced activation of 
renin- angiotensin pathway with increased activity of sympathetic system and 
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arginine vasopressin mechanism. This results in renal sodium and  water  
retention  to maintain  normal homeostasis. Also, splanchnic vasodilation leads 
to increased lymph production and leakage into peritoneal cavity. Both these 
events lead to sustained ascitic fluid formation40. 
CAUSES OF ASCITES14 
Cirrhosis-85%  
OTHERS-15%                       
1. Alcoholic hepatitis 
2. Cancer (peritoneal carcinomatosis,  liver metastasis, etc) 
3. “Mixed” ascites 
4. Pancreatitis  
5. Nephrotic syndrome        
6. TB peritonitis    
7. Heart failure 
8. Acute liver failure 
9. Budd-Chiari syndrome  
10. Postoperative lymphatic leak  
11. Sinusoidal obstruction syndrome  
12. Myxoedema.  
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MIXED ASCITES61 
Have underlying portal hypertension with cirrhosis along with other  
conditions like TB or peritoneal carcinomatosis.  
SECONDARY PERITONITIS40,5,20,54 
Look for it when: 
1. No diminish in ascitic fluid PMN count 48 hours after  antibiotic starting. 
2. Two or more organisms shown on culture 
3. If in ascitic fluid atleast two (2/3) is seen: 
  AF protein  >1g/dl. 
 AF lactate dehydogenase(LDH)>225mU/ml. 
 AF glucose  <50 mg/dl. 
Antibiotics against anaerobes and enterococci have to be added. 
TUBERCULOUS PERITONITIS 
Abdominal tuberculosis is the sixth most frequent site49of tuberculosis. 
Peritoneal TB occurs in three types: 
1. Fibrotic type. 
2. Encysted (loculated) type. 
3. Wet type with ascites.  
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  Macroscopically it   is straw coloured and an exudate (protein>3g/L).  
The total cell count is 500-2000 cells/mm3 with predominant of lymphocytes 
(70%). Lymphocytosis of ascitic fluid means that the lymphocytes account for 
>30% of total AF cell count39. 
Sometimes  PMNs may be abundant (>250/mm3) early in the disease 
and this can lead to misdiagnosis as SBP2,39,45.  
The SAAG has a gradient of <1.1g/dl.  
The adenosine deaminase (ADA) of >33U/L has a sensitivity of 98% 
and specificity of 100% in non-cirrhotic patients4.  
The yield of tubercle bacilli on smear and culture is low and large amounts of 
fluid (about 1L) has to be used for centrifuge and the deposit is inoculated on LJ 
medium. The time taken for growth of tubercle bacilli is usually 6-8 
weeks2,29,45. 
 
 
 
  
12 
 
GRADING OF ASCITES 
THE INTERNATIONAL ASCITES CLUB40 
              Grade one       -Ultrasound detected. 
              Grade Two     -Abdominal distention. 
              Grade Three   -Tense ascites 
TYPES OF ASCITES 
1. Uncomplicated Ascites- Ascitis in the absence of infection/ HRS. 
2. Refractory ascites can be prevented with drug treatment after 
therapeutic paracentesis. 
3. Diuretic- Resistant  ascites - Ascites persists even after high  dose or 
maximum  dose  of  diuretic treatment. 
4. Diuretic- Intractable   ascites - diuretics causing   side   effects leading   
to improper treatment.  
ASCITIC FLUID INFECTIONS (AFI). 
The most common complication of cirrhosis with portal hypertension is 
the ascitic fluid infection (31%) .  
           Ascitic fluid infections (AFIs) has been classified into five variants 
based on analysis of the following parameters- 
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 Polymorphonuclear leukocyte (PMN) count 
 Culture growth and  
  Mode of entry of organism into the fluid66. 
CLASSIFICATION OF ASCITIC FLID INFECTION 
1. Spontaneous Bacterial Peritonitis 
2. Monomicrobial Non-Neutrocytic Ascites  
3. Culture Negative Neutrocytic Ascites 
4. Polymicrobial Bacterascites  
5. Secondary Bacterial Peritonitis 
Criteria for diagnosing Spontaneous Bacterial Peritonitis 
1. PMN count >250cells/mm3. 
2. A positive ascitic fluid culture. 
 Criteria for diagnosing Monomicrobial Non-Neutrocytic Ascites  
1. PMN count < 250cells/mm3. 
2. A positive ascitic fluid culture for a single organism. 
Criteria for diagnosing Culture Negative Neutrocytic Ascites 
1. PMN count  is 250cells/mm3. 
2. Ascitic fluid culture - no organism  
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Criteria for diagnosing Polymicrobial Bacterascites  
1. PMN count < 250cells/mm3. 
2. Ascitic fluid culture – multiple organisms 
Criteria for diagnosing Secondary Bacterial Peritonitis 
1. PMN count  is 250cells/mm3. 
2. Ascitic fluid culture – multiple organisms 
3. Intra abdominal surgically treatable primary infection 
 
SPONTANEOUS BACTERIAL PERITONITIS 
HISTORY 
       It is of historical interest that Ludwig von Beethoven is probably the first 
patient known by the name to have had SBP, especially since the clinical 
description of his case had been written 135 years before this syndrome was 
first described.  
Kerr et al & Conn,  printed papers which explained ascitic fluid infections 
(AFIs) in the absence of contiguous or intra-abdominal source of infection10. 
Conn in 1984  was  the  one  coined  the  term  Spontaneous Bacterial 
Peritonitis (SBP)3.  
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Runyon who has done several works in SBP suggests that we have to now 
drop the term “SPONTANEOUS” since the pathogenesis has been studied and 
worked out25. 
INTRODUCTION  
Spontaneous bacterial peritonitis is an infection of ascitic fluid in the 
absence of any intra-abdominal or surgically treatable source of infection. It is 
diagnosed by a positive culture and ascitic fluid PMN cell count of   ≥250/mm3, 
in the absence of a surgically treatable intra-abdominal source of infection.  
Although SBP has been described in many different clinical settings, like 
nephrotic syndrome, malignant metastatic disease, post necrotic cirrhosis, 
chronic active hepatitis, acute viral hepatitis, congestive heart failure, systemic 
lupus erythematosis (SLE) and lymphedema and also in patients with no 
underlying disease, most episodes develop in adults in conjunction with 
cirrhosis of the liver.  
PREVALANCE  
Ascitic fluid infection is the most frequent infectious complication among 
patients with cirrhosis  with ascites comprising 31% of all bacterial infections in 
the human body.  
The prevalence of SBP in the past was relatively low  5% to 10% in  cirrhotic 
patients with ascites. However the recent studies using newer diagnostic criteria 
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and improved culture techniques have estimated a prevalence of 10% to 30%  
among inpatients and 3.5% among outpatients.  
RISK FACTORS 
 Severity of the liver disease-Child-Pugh class C patients 
 Urinary tract infection and asymptomatic bacteruria14 
 Serum total bilirubin level more than 2.5 mg/dl 
 Gastrointestinal bleeding 
 Increased prothrombin time54 
 Increased liver enzymes54 
 Previous episodes of SBP21 
 Ascitic fluid protein level <1g/dl  
MICROBIOLOGY 
Bacteria most commonly isolated from ascitic fluid in patients with SBP 
are usually those of the normal intestinal flora. More than 92% of all cases are 
monomicrobial with aerobic gram negative bacilli. This is being responsible for 
more than two third of cases.  
Escherichia coli accounts for nearly half of these cases followed by Klebsiella 
spp and other gram negative bacteria. Twenty-five percent of cases are caused 
by gram positive organisms with Streptococcus spp being the most common. In 
bacterial peritonitis associated peritoneal carcinomatosis, the microorganisms 
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isolated are those which are not usually known to cause SBP and quite virulent, 
for example, Salmonella spp. SBP is rarely caused by anaerobic organisms, so 
their presence in ascitic fluid should raise suspicion due to some other cause. In 
other cases, the bacteria may reach the ascitic fluid from the urinary or 
respiratory tracts. 
PATHOGENS IN ASCITIC FLUID INFECTION 
1. Escherichia coli 
2. Klebsiella pneumoniae 
3. Streptococcus pneumonia 
4. Streptococcus viridans 
5. Staphylococcus aureus 
6. Miscellaneous gram positive and gram negative organisms. 
PATHOGENESIS  
GENERAL CONCEPT  
Although the pathogenesis of SBP is not completely understood, it is 
thought that it occurs as a consequence of translocation of bacteria across the gut 
wall to the intestinal lymph nodes, with subsequent bacteremia and infection of 
the ascitic fluid. 
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It is generally accepted that it involves three major steps: 
 Passage of bacteria from the intestinal lumen, or from other sources in a 
lower proportion of cases to the systemic circulation.  
 Bacteremia secondary to the impairment of the reticulo endothelial 
system (RES) phagocytic activity. 
 Infection of ascites due to defective bactericidal activity of the ascitic 
fluid.  
Studies in experimental animals with cirrhosis suggest that the first step in the 
passage of bacteria from the intestinal lumen to the ascitic fluid is the 
colonization of mesenteric lymph nodes, a process known as bacterial 
translocation. 
Evidences  supporting this mechanism includes: 
 The isolation of gram-negative bacilli from mesenteric lymph nodes in a 
large proportion of cirrhotic rats with ascites 
 Isolation of the same bacteria from lymph nodes and ascites in most cases 
 The presence of histologic abnormalities in the intestinal wall, such as 
submucosal edema involving the cecum and ileal lymphangiectasia. All  
these may facilitate the translocation process.  
Transmigration across the gut wall is the most likely mechanism by which 
bacteria from the intestinal lumen reaches the mesenteric lymph nodes. 
Intestinal bacterial overgrowth and impaired small bowel motility, which are 
20 
 
common in both experimental and human cirrhosis, may facilitate bacterial 
translocation. 
THE POSSIBLE ROUTES OF ENTRY OF BACTERIA  
1. Organisms can come directly from the gastrointestinal tract, or from the 
blood stream.  
2. The rarest route is through the Fallopian tubes. This route of entry has 
been implicated by McCartney to explain the predominance of girls 
with primary peritonitis. (5) 
The   most   common   causes   of   bacterial   peritonitis:    
 Perforations of ulcers of upper gastrointestinal tract. 
 The rupture of abdominal viscera, usually the appendix.  
Although perforations of the gastrointestinal tract may be clinically silent, and 
even when silent they usually exhibit pneumoperitoneum. Under certain 
conditions bacteria may enter the peritoneal cavity by traversing the intact 
intestinal wall66. 
BACTERIAL OVERGROWTH 
Bacterial overgrowth occurs from  
 Overgrowth of  a  single species  of  indigenous  bacteria  in  the  
intestinal  tract.  
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 Immunosuppressive conditions like HIV, diabetes.   
 Thermal injuries in which large segments of skin are burned,  
 Haemorrhagic, hypotensive shock, i.e., insufficient blood supply to the 
gastrointestinal (GI)   tract.  
 In addition, specific disorders of  the  Gastrointestinal  tract,  such  as  
intestinal  or  biliary  obstruction  or  portal hypertension, may all give 
rise to Bacterial overgrowth31.  
ROLE OF HEPATIC LYMPHATICS 
It  is  possible that  the  hepatic lymphatics themselves may be 
involved in the pathogenesis of SBP. Hepatic lymph is the key to the formation 
of ascites. In cirrhotic patients when there is hepatic venous outflow 
obstruction, the production of hepatic lymph is increased resulting in the 
formation of ascites, largely due to the exudation of hepatic lymph directly into 
the peritoneal cavity31. 
THE FACTORS PRONE TO DEVELOP SBP 
Failure of hepatic removal of bacteria from the blood stream. McIndoe 
described the extrahepatic portal-systemic collateral networks that shunt portal 
venous blood around the liver. 
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These  portal -systemic shunts have been shown to diminish  the hepatic 
clearance of ammonia and other n i t r o g e n o u s  substances absorbed from 
the gastrointestinal tract. By these portal-systemic anastomoses, the circulating 
bacteria bypass the hepatic reticuloendothelial filtering system, which has been 
shown to be the major site of removal of bacteria from the blood.   Decreased 
hepatic removal of circulating bacteria tends to perpetuate bacteremia and thus 
afford circulating organisms, a greater opportunity to cause    infections   at 
susceptible sites such as ascitic fluid.41,42 
Normally the portal venous blood is aseptic. In case of migration of 
bacteria from infected lumen , they are getting trapped and removed by  the  
liver.  Cirrhotics have  increased and  abnormal bowel  flora41. Bacterial 
overgrowth is increased in cirrhosis by delayed intestinal transit, decreased 
luminal IgA and bile salts.66  
DELAYED INTESTINAL MOTILITY 
Normal  distal movements of the luminal contents by peristalsis helps to 
avoid colonization and multiplication of bacteria in the upper intestine. This 
movement is facilitated by MMC (MIGRATORY MOTOR COMPLEX) -the 
“intestinal housekeeper”. The complete or partial absence of the phase III 
activity of MMC results in bacterial overgrowth17. In cirrhosis, there is 
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increase in bacterial colonization of the small bowel (31-53%) with bacteria 
from the large bowel38. 
INTESTINAL MUCOSAL BARRIER  
SECRETORY  MECHANISM (1
st 
 LINE DEFENCE) 
The goblet cells of intestinal epithelium secret  mucins   that acts as 
electro- negative charged layer preventing the direct contact between bacteria 
and intestinal membrane. In cirrhotic patients with sepsis there is an elevated 
permeability of intestinal mucosa due  to  oxidative stress, elevated Nitric 
Oxide, endotoxins, various proinflammatory cytokines, and enterocyte 
mitochondria malfunction .38 
IMMUNOGLOBULIN  A 
70%  of  body’s immunoglobulin production  is  IgA. In cirrhotics  patients 
there is diminished production of mucosal IgA17,38.12. 
BILE’S TROPHIC EFFECT 
Bile inhibits intestinal bacterial overgrowth;  
Bile has detergent action and anti-adherence properties, endotoxin removal, 
trophic effect for intestinal mucosa with decreased epithelial bacteria 
internalisation. The quantity of bile acids in liver disease is diminished due to 
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decreased secretion and accentuated deconjugation of bile by intestinal flora. It 
aids in bacterial translocation caused  by endotoxins17,38. 
THE PHYSICAL MECHANISM (2nd LINE DEFENCE)  
INTESTINAL EPITHELIAL STRUCTURE 
Tight  junctions between the cells   located at   the apicolateral surface of 
the epithelium inhibits the transport of bacteria or  its lipopolysaccharide.  
In liver disease  there is  widening of intercalated cells, decrease in the 
number of crypts and villus, Vasodilation, oedema of muscularis mucosae and 
fibromuscular proliferation. All these factors breaks the integrity of the 
normal epithelium38. 
 NATURAL  ANTIBIOTIC SECRETION 
 Paneth cells in the   jejunal and ileal crypts produce - phospholipase A2, 
defensins, and lysozyme, cryptidin related signal peptides,  which have 
natural antibiotic property. 
 Small intestine epithelial cells and Colonic epithelial cells secrete      
defensins that defend against commensal bacteria.  
In chronic liver disease  secretion of   these  substances with antimicrobial 
activity is reduced.13  
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GUT ASSOCIATED LYMPHOID TISSUE. 
Four  components 
1. Lymphocytes from the lamina propria.  
2. Intraepithelial lymphocytes 
3. Mesentric lymph nodes (MLN) 
4. Peyer’s patches 
When the Bacteria interact with the structures in the Gut Associated   T 
Lymphocytes,   there   is   multiplication   of   lymphocytes in the germinal 
centers of reticuloendothelial system and so the mucosal immunoglobulin 
secretion gets elevated 38.  
The primary immune response was associated with monocytes. By its 
interaction of  PRR -PATTERN RECOGNITION RECEPTOR with specific 
bacterial ligands PAMPs -PATHOGEN ASSOCIATED MOLECULAR 
PATTERNS, the antigens are taken  up by the dendritic cells through  the  local  
antigen presenting  cells  (APCs) –DIRECT MECHANISM and by M cells 
which overtake the antigen by endocytosis- INDIRECT MECHANISM 38.  
Microbial peptides are presented by the Antigen presenting cells to the 
B & T lymphocytes. This will result in the  secretion of mucosal IgA (or IgG) 
or its transformation into Th1 and Th2 cells. On exposure to the antigen, the T 
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lymphocyte  from  the  Peyer’s    patches14  move towards lamina propria 
and  gets tranformed into  CD8   T – lymphocytes.  Impaired  primary  and  
adaptive  immune response occurs in DCLD38,17  
BACTERIAL TRANSLOCATION 
      Portal hypertension causes venous stasis, hypoxia of the mucosa and 
oxidative stress induced cytotoxic   damage28,30. This leads to splanchnic 
dilatation with Mucosal congestion and Bowel Oedema leading to altered 
bowel permeability and bacterial translocation to mesentric lymph nodes40. 
Gram negative bacteria are more adapt than Gram positives and anaerobes in 
translocation66.Bacteria generally do not migrate directly from the lumen into 
ascitic fluid. It happens if there is a loss of mucosal integrity.  
Anaerobes are present in excess in gut flora which  translocate only in  
intestinal   mechanical   injury   and   are occasionally isolated from ascetic 
fluid in SBP66,17.  
More virulent organisms and Escherichia coli strains with greater 
adherence to intestinal mucosa  translocate more  precisely 21. 
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INVASION OF ASCITIC FLUID AND BACTEREMIA 
Splanchnic and systemic vascular dilatation results in hyperdynamic 
circulatory state with elevated cardiac output and drop in blood pressure21. 
Due to the high circulatory state,  due to spilling over of the organisms from 
mesenteric lymph nodes into systemic circulation results in bacteremia.15Due  
to   the  diminished  phagocytosis  of reticuloendothelial system, the bacteria 
stays uncleared from the circulation for a long period66. In cirrhotic patients 
due to the presence of   intra  and  extra  hepatic  shunts  the  bacteria never    
come  into alignment     with     the     Kuffer     cells     and  thus   the  
bacteremia increases77. Bacteremia  results in oozing of infected fluid through 
Glisson capsule and oozing of infected interstitial fluid from intestinal 
capillaries leads to colonisation of ascitic fluid. 
SBP AND BACTERASCITES 
Opsonins level and C3 complement level are decreased in DCLD. Low 
protein concentration (<1g/dl) have  positive correlation with decreased opsonic 
activity.  
Opsonins and macrophages were not able to kill the bacteria and so the 
neutrophils are allowed to do the killing process. SBP occurs, since there  is 
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impaired neutrophil function  or  qualitative neutrophil 
abnormalities.40,58,66,17. 
SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME.  
Lipopolysaccharides and peptidoglycans in the bacteria can trigger the 
TLR receptors16 that leads to the production of various pro-inflammatory 
cytokines. This leads to inadequate tissue perfusion, multi-organ failure 
(MODS), refractory hypotension, sepsis   syndrome  pathways finally results in 
death.21,42,58. 
SIGNS AND SYMPTOMS OF SBP 
The most common reported are: 
 Fever(68%) 
 Abdominal pain(68%) 
 Hepatic encephalopathy(53%) 
 Ileus or Diarrhea(31%) 
 Vomiting(20%) 
 About 14% of patients with SBP are asymptomatic37,63. 
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HEPATORENAL SYNDROME
4
 
The  annual  incidence  of  HRS  in  patients  with  ascites  is 10%. 
There  is  no  major  change  in  renal  biopsy  and  is  completely relieved by 
liver transplantation. 
New Diagnostic criteria of the hepatorenal syndrome12. 
 Cirrhosis with ascites 
 Serum creatinine >1.5 mg/dL (133μmol/L) 
 No improvement in serum creatinine (decrease to a level of 1.5 mg/dL or 
less) after at least 2 days of diuretic withdrawal and volume expansion 
with albumin 1 g/kg of body weight per day up to a maximum of 100 
g/day 
 Absence of shock 
 No current or recent exposure to nephrotoxic drugs 
 Absence of parenchymal kidney disease as indicated by proteinuria of 
>500 mg/day, hematuria (>50 red blood cells    per    high    power    
field),    and/or    abnormal    renal ultrasonography 
Adapted from Salerno et al. [12]. 
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HRS TYPE 1 
       Renal failure with increased serum creatinine reaching >2.5mg%(12) in 
<2 weeks. It may occur spontaneously or it can be precipitated by bacterial 
infections, gastrointestinal bleeding or acute hepatitis super imposed on 
cirrhosis. It develops in 30% of inpatients with SBP32. 
HRS TYPE 2 
Moderate and steady decrease in renal function over months (serum 
creatinine < 2.5 mg/dl). There is severe ascites with poor or no response to 
diuretics (refractory ascites). 
CHILD TURCOTTE PUGH (CTP) SCORE61 
 Initially it was used to prognosticate the short term mortality, it is now 
used   to   assess   the   prognosis   and   the   requirement   for   liver 
transplantation. It contains parameters five parameters like total bilirubin, 
serum albumin, PT-INR, ascites and hepatic encephalopathy. 
A : 5-6 points. 
B : 7-9 points. 
C : 10-15 points 
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S.No VARIABLE 1POINT 2POINTS 3POINTS 
1. Total bilirubin <2mg/dl 2-3mg/dl >3mg/dl 
2. Albumin >3.5g/dl 2.8-3.5g/dl <2.8g/dl 
3. INR <1.7 1.7-2.2 >2.2 
   4. Ascites No 
Mild(Medically 
controlled) 
Severe(Poorly         
controlled) 
   5. 
Hepatic 
Encephalopathy 
No 
GradeI-II 
(Medically 
controlled) 
GradeIII-IV (Poorly 
controlled) 
 
MODEL FOR END- STAGE LIVER DISEASE (MELD) SCORE50  
 Includes three lab objectives  
 International normalized ratio(INR), 
 Serum creatinine and  
 Serum bilirubin.  
MELD=9.57×loge(creatinine)+3.78×loge(totalbilirubin)+11.2× loge(INR) + 
6.43. MELD is better than CTP in evaluating the mortality following variceal 
bleeding. Addition of  the renal parameter creatinine  explains its importance in 
evaluation of mortality risk. CTP has more variabilites than MELD. Also 
MELD has wider possible scores and offers more weightage than CTP. Patients 
with high MELD score (>15) are more prone for infections and mortality than 
patients with low MELD score (<15). 
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RECOMMENDATIONS FOR DIAGNOSIS OF AFIs. 
The AFIs  clinically present  with single or multiple symptoms. 
Considerable elapse of time leads to raised morbidity and mortality. The 
diagnosis is primarily on ascitic fluid analysis5,40,3. 
INDICATIONS FOR DIAGNOSTIC PARACENTESIS3,5,37 
 New onset ascites. 
 Localising signs of peritonitis mentioned above.22 
 At the time of each admission to hospital. 
 In gastrointestinal bleeding prior to antibiotic prophylaxis. 
 Laboratory test (LFT) abnormalities. 
 Rapid impairement in renal function. 
Paracentesis is safe despite the predictable coagulopathy in cirrhotic    patients.  
COMPLICATIONS OF PARACENTESIS 
 Prolonged leakage – most common 
 Abdominal wall haematoma-2%    
 Haemoperitoneum –0.02%  
 Iatrogenic infections- 0.02% (0.7%),  
 Visceral perforation- 0.7% 
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ASCITIC FLUID LABORATORY DATA 
TESTS ROUTINELY DONE 
 Cell counts with differential count. 
 Culture. 
 Gram’s stain23 
 Total protein including albumin 
 Lactate dehydrogenase 
 Glucose 
 Amylase 
These tests also help to readily differentiate and identify the various etiologies of 
ascites besides from portal hypertension. The SAAG (Serum-ascites albumin 
gradient) helps in indentifying the presence of portal hypertension.14  
CORRECTED SAAG  
In serum hyperglobulinemia of  >5gm/dl, narrow SAAG gradient occurs 
in 1% of ascitic fluid specimen. 
CORRECTED SAAG = Uncorrected SAAG × 0.16 × (serum globulin [g/dl] + 2.5) 
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CAUSES OF LOW GRADIENT (SAAG<1.1g/dl) ASCITES14 
 TB-AF LDH (<250 U/ml) and low glucose level. 
 Pancreatic ascites 
 Malignancy induced ascites-AF LDH and high glucose level. 
 Biliary ascites 
 Renal ascites 
MACROSCOPY: GROSS APPEARANCE OF ASCITIC FLUID 
 Crystal clear- protein level decreased 
 Transparent and yellow-Non- neutrocytic ascites (PMN<250/mm3) 
 Cloudy- Cells value of 5000/mm3 is cloudy, and greater than  
50,000/mm3 appears  mayonnaise. 
 Bloody- Ascitic Fluid RBCs of 10,000/mm3 is the maximum. 
 RBC  >20,000/mm3 is  hepatocellular carcinoma.  
 Chylous/milky – Ascitic fluid with Triglyceride >200mg% 
 Dark brown- Biliary concentration more than that of serum, due to   
biliary perforation. 
IMPORTANCE OF CELL COUNT 
The ascitic fluid POLYMORHONUCLEAR LEUKOCYTES count 
(maximum> 250 cells/mm3) is the efficient test for diagnosis of AFI. But PMN 
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count above this value can also be found in bleeding into the ascites, peritoneal 
carcinomatosis and pancreatic ascites 66. In tuberculous or malignant ascites, 
lymphocytes will increase. 
MANUAL VS AUTOMATED COUNTING 
The laboratory should perform the cell count within 60 minutes. The 
manual count is error-prone and subjective and  it also retards the start of ever 
needed empirical antibiotic therapy3,13,69. Automated cell counters are ideal 
but the manufacturers do not recommend it for fluids other than blood13. This 
can be useful if further validated14. 
GRAM STAINING 
Gram staining is not recommended in the diagnosis of SBP. Gram stain is 
insensitive in detecting SBP and is associated with a high false positive rate.  
DIPSTICK TEST 
Testing of ascitic fluid using leukocyte esterase dipsticks is simple and 
Inexpensive method and can be performed at the bedside. The results are 
available within a maximum of 2 minutes. It is a useful test in the area  
which is less equipped or understaffed and where culture is  not available or 
takes too long time to get results.  
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ASCITIC FLUID LACTOFERIN 
Measuring ascitic fluid lactoferin, which is a proposed marker of SBP, 
was done, involving 148 patients with ascites. Sensitivity and specificity were 
96 and 87 percent, respectively, using a cut-off level of 242 ng/mL.  
However more studies for validation of this test are needed.  
RELAVENT ADDITIONAL INVESTIGATIONS3,5 
1. Blood cultures associated with the ascitic fluid cultures- positive in 
atleast 1/3 rd of cases26. 
2. Complete blood count 
3. WBC count may be low inspite of the presence of SBP due to   
Hypersplenism57. 
4. Urine analysis and urine culture-asymptomatic bacteriuria is an    
independent risk factor14. 
TREATMENT  
Spontaneous Bacterial Peritonitis – 
Cefotaxime 2gm IV every 8
th
 hourly Metronidazole 500mg IV 8
th 
hourly empirically followed by specific antibiotics according to culture and 
sensitivity. 
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PROPHYLAXIS  
SELECTIVE INTESTINAL DECONTAMINATION 
(SID)23,36,37 
Norfloxacin is recommended : 
Poor intestinal absorption and it rapidly diffuses into the ascitic fluid. Preserves   
anaerobes  and  prevents  gut  colonization  by  pathogenic bacteria. Strong  
activity against gram negative bacteria. 
INDICATIONS 
Patient with Gastrointestinal bleeding 
 Norfloxacin 400mg BD for 7 days. 
Ascitic fluid protein <1 gm% Previous history of SBP 
Newer quinolones are preferred since apart from eliminating gram   negative 
bacteria, it decreases bacterial adhesion to mucosa, and they also stimulate 
bactericidal capacity of PMNs. 
Patients who survive an episode of SBP have 41 to 71% chance of relapse in 
the forecoming 13 months. Hence, long term administration of quinolones is 
advocated for these patients till they are having symptoms and signs of ascites, 
transplantation or death. 
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But this approach selects quinolone resistant GNB and trend towards infection 
caused by GPC. For patients on quinolone prophylaxis who develop an SBP 
episode, third generation cephalosporins are the best option. 
DISEASE SEVERITY AND CLINICAL OUTCOME 
Studies have shown that the mortality rate due to spontaneous bacterial 
peritonitis in hospitalized patients in the past was around 80% to 90%.  
However, widespread use of diagnostic paracentesis with the higher index of 
suspicion of infection, with various diagnostic criteria, together with use of 
better and safer antibiotics, has significantly improved the short-term prognosis 
in SBP patients.  Currently, there are essentially no deaths as a result SBP, 
provided it is detected and treated before the development of its complications 
likes hock or renal failure.  
Though the prognosis of SBP has improved in recent years with the 
advent of effective antibiotics and quick intervention, the long-term prognosis 
of  SBP remains extremely poor among survivors of an episode of SBP, due to 
the manifestation of severe impairment of liver function.  
Probabilities of survival for 1 and 2 years are in the range of 20% and 
30% respectively and in some cases 30 to 50%. Liver transplantation should be 
considered for patients who survive an episode of SBP . SBP is deadly and 
reports since 1970 shows that, the mortality rate exceeded 90% . 
Factors associated with poor outcome include several indicators of poor 
liver function such as the development of renal failure, hepatic encephalopathy, 
39 
 
high levels of serum bilirubin, and upper gastrointestinal bleeding. The 
development of renal impairment after the diagnosis of SBP is probably the 
strongest independent predictor of death.  
In a study by Follo et al. in 252 consecutive episodes of SBP, the 
mortality rate was 100% when associated with progressive renal impairment, 
31%  when associated with stable renal impairment, and only 7% in those 
without renal impairment. 
PLATELETS 
HISTORY 
 
Platelets are small anucleate cells playing a critical role in haemostasis 
and Thrombosis70. Platelets were described by ADDISON in 1841 as 
―extremely minute granules in clotting blood and were termed platelets by 
Bizzozero, who observed their adhesive qualities as increased stickiness when 
a vessel is damaged. 
PLATELET FORMATION 
MEGAKARYOCYTE  DEVELOPMENT. 
Megakaryocytes are the myeloid cells(constituting less than 1% of these 
cells) residing primarily in the bone marrow but  also found in the lung and 
peripheral blood. In early development, megakaryopoiesis occurs within the 
fetal liver and yolk sac. Megakaryocytes arise from pluripotent stem cell that 
develop into 2 types of precursors, burst-forming cells and colony-forming 
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cells, expresses the CD34 antigen72. Thrombopoietin (TPO), the primary 
regulator of thrombopoiesis, is currently the only known cytokine required for 
megakaryocytes to maintain a constant platelet mass. The other regulators 
include IL-3, IL-6, and IL-11, and are not essential for megakaryocyte 
maturation72. 
THE FLOW MODEL OF PLATELET FORMATION. 
Platelets are assembled along essential intermediate pseudopodial 
extensions, called proplatelets, generated by the outflow and evagination of the 
extensive internal membrane system of the mature megakaryocyte 
(proplatelet theory).  The proplatelet and platelet formation process generally 
commences from a single site on the megakaryocyte where 1 or more 
broad pseudopodia form. Over a period of 4–10 hours, the pseudopodial 
processes continue to elongate and become tapered into proplatelets with an 
average diameter of 2–4 μm. The generation of additional proplatelets continues 
at or near the original site of proplatelet formation and spreads in a wavelike 
fashion throughout the remainder of the cell until the megakaryocyte 
cytoplasm is entirely transformed into an extensive and complex network of 
interconnected proplatelets. 
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PLATELET LIFE SPAN 
The   average lifespan of platelets is 7-10 days. 
Platelets are lost from circulation by two mechanisms:  
 Senescence  
  Random removal in endothelial supportive functions of a 
fixed fraction of platelets amounting 7.1x109/l/day.  
Senescent platelets are removed primarily by macrophages in the 
spleen, although the larger blood flow through the liver allows severely 
damaged platelets to be removed more quickly by hepatic macrophages.  
LIGHT MICROSCOPY 
Wright-stained smears reveals platelets are small, anucleate 
fragments with occasional reddish granules, measures 
approximately 2μm in diameter with a volume of approximately 8fl72 
and with considerable variation in size and shape. 
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ELECTRON MICROSCOPY AND SUB-CELLULAR FEATURES 
Platelets exist in two distinct forms:  
    Resting form - baseline metabolic activity 
    Activated form - agonist stimulation (i.e., response to thrombin).  
 
 
 
 
 
 
 
 
Figure. Resting and activated platelets* 
 
Platelets change their structure during the resting to activated transition.  
 
 Platelet structure is classified into four general areas:  
     
  Platelet surface.  
     
 Membrane structures. 
 
 Cytoskeleton.  
 
 Granules.  
 
  
PLATELET SURFACE 
Plasma Membrane: 20nm thick trilaminar structure.73 The membrane 
is exceptionally complex in composition, distribution, and function.  It 
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incorporates a number of glycoproteins and lipids into its phospholipid bi-layer 
and integrates a variety of events such as permeability, agonist stimulation, 
and platelet adhesion, activation/secretion, and aggregation. 
Glycocalyx: A fuzzy layer of lipids, sugars, and proteins.15-20 nm thick. It 
coats the outer surface of the platelet plasma membrane. This layer 
provides a transfer point for plasma proteins such as fibrinogen as they are  
taken up into secretory granules by endocytosis75. The glycocalyx contains 
glycoproteins, glycolipids, mucopolysaccharides, and absorbed plasma proteins. 
It produces a net negative surface charge mainly due to sialic acid residues on 
certain protein such as gpIb76. This protein is thought to minimize the  
attachment of circulating platelets to each other and to vessels 
PLATELET MEMBRANOUS SYSTEMS 
 Platelets membrane have  high content of actin and they have 
contractile response during activation. Similar muscle like qualities found in 
the two membranous systems of platelets, the SCCS and the dense tubular 
system, which resemble transverse tubules and sarcotubules, respectively 76 
PLATELET CYTOSKELETON 
Both the shape of platelets and their ability to contract and spread depend 
on the cytoskeleton77.The cytoskeleton can direct platelet shape 
change, send out extracellular extensions, collect and then extrude 
secretory granules, and affect surface activity. These functions are 
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performed by three distinct structures: 
1. The membrane skeleton, which buttresses the inner side of the 
plasma membrane. 
2 .  The mass of actin and intermediate filaments, which fills the 
cytoplasm. 
3 .  The circumferential microtubule band, which encircles the 
substance of the platelet to produce the resting disclike form. 
 PLATELET GRANULES AND ORGANELLES 
 PLATELET GRANULES 
   Normal platelet function appears to require some amplification  of any given 
stimulus to obtain an appropriate response. The  platelets possess secretory 
granules and mechanism that serve this purpose by releasing additional 
stimulatory materials, that are previously sequestered within the resting 
platelet.   
Two main secretory granules, the α-granules and the dense bodies 
contain highly reactive  contents adenosine diphosphate (ADP) and 
fibrinogen respectively. Platelet granule secretion begins with a dramatic 
increase in platelet metabolic activity, stimulated by calcium release and 
results in  increased adenosine phosphate (ATP) production  
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ORGANELLES 
Microperoxisomes: are small 90 nm in diameter granules, demonstrable with 
alkaline diamino benzidine due to their catalase activity. It   may participate in 
the synthesis of platelet-activating factor, but its ultimate fate within the platelet 
cytoplasm is unknown74. Coated vesicles are 70 to 90 nm in diameter. The 
polyhedral surface coat is composed of clathrin,.  
Mitochondria: Mitochondria in platelets are smaller size. There are 
approximately seven per human platelet. They serve as the site for the actions of 
the respiratory chain and the citric acid cycle78. Glycogen is found in small 
particles or in masses of closely associated particles, play an essential role in 
platelet metabolism. 
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PLATELET FUNCTION AND INFLAMMATION 
Hemostasis and inflammation are closely linked and are often activated 
concomitantly
 80
 . In response to inflammatory stimuli, circulating leukocytes 
roll and then adhere on the endothelial cells and finally migrate into the 
surrounding tissues. In response to vascular damage, circulating platelets 
adhere to the subendothelial tissues and then recruit more platelets to form 
aggregates that function as procoagulants 80. These processes are  mediated by 
cell adhesion molecules.  
Platelet adhesion receptors are classified into four groups based on their 
molecular structure:  
1. Selectins (P-selectin), 
2. Integrins (e.g. GPIa-IIa, GPIIb/IIIa), 
3. Leucine-rich glycoproteins (GPIb-V-IX and GPIV) and  
4. Receptors of the immunoglobulin type (ICAM-1and 
PECAM1) 
Selectins- mediate the early tethering and rolling of leukocytes on the vascular 
endothelium, causing weak attachment of leukocytes to the vessel wall. 
Integrins- enable firm adhesion of leukocytes to the vascular endothelium.  
Immunoglobulins- mediate migration of leukocytes from endothelial cells into 
the surrounding tissues 81. 
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Migrating poly-morphonuclear leukocytes (PMNs)- also carry adhering 
platelets to inflammatory extravascular tissue 38. 
P-selectin expression 
P-selectin is an integral membrane protein located in the alpha-granules of the 
platelets. 74 It is expressed on the cell surface during cell activation. This 
protein mediates interactions between platelets, leukocytes and endothelial 
cells. P-selectin stabilizes initial platelet aggregation75 and synergizes with 
platelet activating factor (PAF) and/or RANTES and induce the synthesis of 
cytokines like interleukin-8 (IL-8) and tumour necrosis factor-alpha (TNF-α) 
and monocyte chemo attractant protein1 (MCP-1),thus providing localized 
signals for monocyte adhesion 43.  
Soluble P-selectin 
The expression of P-selectin is transient, as it is endocytosed 45 or 
proteolytically shed from the platelet surface into plasma in a biologically 
active soluble form, while the platelet continues to circulate and function 
Soluble P-selectin is found to be dependent on the time of sample collection 
and related to platelet count 46, 47 and it has been proposed to be a reliable 
marker for in vivo platelet activation 48, 49.  
P-selectin in plasma may also be partly derived from the endothelium since P 
selectin is a component of the membrane of the Weibel Palade bodies in these cells  
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CD40 ligand (CD40L) 
CD40L, a member of the TNF-α family  is also expressed by platelets 
50. By  stimulating the  platelets with ADP or thrombin, CD40L is rapidly 
mobilized from intracellular granules to the platelet surface and trigger an 
inflammatory response on endothelial cells 50. CD40L is rapidly cleaved into 
a soluble form, sCD40L, and shed from the platelet surface in minutes to 
hours.  
Interestingly, GPIIb/IIIa antagonists block the hydrolysis and 
subsequent release of sCD40L from the platelets. So  biological activites of 
sCD40L can be retained by virtue of sCD40L to bind to GPIIb/IIIa 52 
Platelet-leukocyte aggregates 
Platelet-leukocyte aggregates represent an interface between 
inflammatory, atherogenic and thrombogenic responses. The propensity to 
form heterotypic aggregates differs between leukocyte subpopulations, with 
monocytes showing the greatest and lymphocytes the least propensity. PMN 
and platelet-monocyte interactions mediate targeting of leukocytes to the 
site of injury and may enhance the synthesis of chemokines and cytokines 
and adhesion molecules, thus further increasing platelet and leukocyte 
reactivity 38.  
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PHYSIOLOGY OF PLATELET SIZE 
MPV appears to be a marker, or even a determinant, of platelet 
function. Large platelets are more reactive than small platelets in vitro. They 
preferentially and more rapidly aggregate with platelet agonist like ADP, 
collagen and adrenaline produce more prothrombotic and vasoactive factors 
including arachidonic acid metabolites (eg. Thromboxane A2), serotonin, β 
thromboglobulin and ATP. They are associated with a decreased bleeding 
time (BT; a measure of in vivo haemostatic function). 
 
PLATELET INDICES 
Similar to RBC, several indices have been derived from platelets.   
The most commonly used are  
 Mean Platelet Volume (MPV) and 
 Platelet  Distribution Width(PDW).  
 
MEAN PLATELET VOLUME (MPV) 
Measurement of peripheral blood platelet count tells little about platelet 
related haemostatic function. However, most haematology analysers,  
measure another platelet parameter, the mean platelet volume which can give 
useful clinical and patho-physiological information about patients and vascular 
diseases.8 
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MEASUREMENT OF PLATELET VOLUME 
  
The optimal method for measuring platelet volume  
 
 electrical impedance (Coulter haematology analyser). 
 
 light diffraction (Technicon).  
 
 
Alternative and less satisfactory methods includes 
 
 semi-quantitative measurement of diameter on platelet smears. 
 
 flow cytometry8. 
  
 
In the Coulter series, cells held in fluid suspension are allowed to flow 
through a small aperture, which create a change in voltage, proportional to 
particle size. A raw histogram is generated, and a log-normal curve is fitted to 
the data. Platelet count is derived from this together with the MPV, which is 
calculated by numerical integration. Similarly, the Sysmex measures 
parameters with cells in fluid suspension, in addition,  the cells are hydro 
dynamically focused, ensuring that the cells travel in a straight line through 
the aperture. This prevents cells flowing through at the edge of the aperture 
and causing spurious changes in the electrical field. It  differs from that of 
Coulter in that the upper and lower discriminators are both mobile1. The 
distribution curve obtained is thus the actual data and not a fitted curve.  
MPV is calculated from the curve by a formula  
(MPV (fL)=Pct (%)x1000÷Plt (x103/μL)).  
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In contrast, Technicon instruments  uses laser-optic technology to measure the 
size and granularity of cells in suspension. A beam of light is passed 
through cells, and the amount of forward scatter is proportional to the size 
of the particles, whereas side scatter equates to the density or granularity. A 
platelet histogram is derived from this data, and MPV is calculated as the 
mode. Differences of up to 40% have been found when Coulter and Technicon 
results have been compared.1 
Complete blood count specimens are usually anticoagulated with EDTA 
that causes platelet to swell in a time dependent manner. Most of the 
increase in MPV occurs during the first 2 hrs but the process continues over the 
next 24 hrs. EDTA is thought to increase intracellular cyclic AMP and 
change plasma membrane permeability1. 
This situation is further complicated since analysers utilising light 
diffraction measures the  particle size by assessing optical density. These 
analysers record a decreasing MPV with time since platelet swelling results in 
a lower optical density. As a result, studies using raw MPV measurements 
made in EDTA are of questionable in clinical or research value unless MPV 
is assessed at a consistent time following  phlebotomy, or once the swelling 
has ceased at 24 hrs. In contrast MPV measured in high concentration 
sodium citrate does not change with time8 and hence considered as the gold 
standard anticoagulant. 
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NORMAL VALUES FOR MPV 
The normal range for platelet volume has yet to be adequately determined, 
but studies measuring MPV in sodium citrate in normal subjects suggest a 
normal range of 4.5 – 8.5 fl with a mean of 6.5 fl8. The day to day 
variation in MPV is small compared with the platelet count.  
ROLE OF MEAN PLATELET VOLUME 
Some studies have shown that MPV has increased in myocardial 
infarction, cerebrovascular accident, Alzheimer disease, hypertension and celiac 
diseases. In contrast it has been shown that MPV decreases in various 
inflammatory diseases like Rheumatoid arthritis, Ankylosing spondylitis, 
Ulcerative colitis and acute pancreatitis. It has been suggested that the the dual 
role of this marker largely depend upon the intensity of inflammation. 
Circulating platelets are abundant source of various pro-inflammatory 
mediators and pro thrombotic factors. Thee play a key role in the initiation and 
propagation of inflammatory and vascular events. Platelets are anucleate cells 
and their size mostly depends on the fragmentation of megakaryocytes. Studies 
have shown that cytokines such as interlukin 3 and interlukin 6 influence 
megakaryocyte ploidy and can lead to the production of large and reactive 
platelets. Thus Mean Platelet Volume (MPV) have been proposed as an indirect 
marker of platelet reactivity. 
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                             MATERIALS AND METHODS 
STUDY TYPE 
Cross - Sectional Study. 
STUDY PLACE 
This study was done in Department of Medicine, Kilpauk Medical 
College in association with the Department of Medical Gastroenterology, 
Microbiology and Pathology, Government Kilpauk hospital, Chennai. 
STUDY PERIOD 
March 2014 – September 2014. 
STUDY POPULATION 
During this period 75 cases of cirrhosis with ascitis who are admitted 
under the  Department of Medicine and the patients attending outpatient 
department, Department of Medical Gastroenterology, Govt. Kilpauk Hospital 
were examined for Ascitic fluid Infections (AFIs). 
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INCLUSION CRITERIA 
 Age more than 18 years. 
 All  inpatients and out patients with  Decompensated  Liver  Disease  
(DCLD), before the first dose of antibiotic administration. 
    EXCLUSION CRITERIA 
 Patients who received antibiotics prior to hospitalization. 
 Patients with hollow viscus perforation and secondary bacterial 
peritonitis. 
 Systemic inflammatory diseases. 
 Cerebrovascular accident. 
 Myocardial infarction.  
INFORMED CONSENT 
Written informed consent was obtained from each patient. If patients 
were unable to provide consent, written consent was obtained from their legal 
guardians (father, mother, spouse, son or daughter). Patients who were unable to 
provide consent and were not accompanied by a legal guardian were not 
enrolled in the study.  
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ETHICAL CONSIDERATION 
Ethical with research clearance was obtained from the Ethical Committee 
Kilpauk  Medical College. Written consent done before enrolment. 
STATISTICAL DATA 
Statistical data obtained with SPSS Software (Statistical Package for 
Social Sciences) version 20. Univariate analysis was done using Pearson Chi-
Square Test and Fisher’s Exact Test. 
SAMPLE COLLECTION61  
After history taking and physical examination, all patients proved to have 
portal hypertension and ascites clinically (i.e., presence of ascites and 
splenomegaly) and by bedside ultrasonography, who met the above mentioned 
criteria during the study period, were cordially invited in the study. Consent 
forms were provided, and the aim of the study was explained. After obtaining 
written informed consent, patients were enrolled in the study. 
MEAN PLATELET VOLUME DETERMINATION 
At the time of admission, the skin to be punctured is sterilised with 60% 
ethanol and allowed to dry. 3ml of blood were drawn and put in the EDTA 
containing sample bottles. 
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EDTA blood samples collected at the time of admission were analyzed in 
automated hematology analysis system. This system measures the platelet size 
using aperture impedance technology. 
All patients samples were processed within 2 hours to avoid bias due to 
excessive platelet swelling. Previous studies reported that MPV values increase 
due to platelet swelling when EDTA was used as an anticoagulant. However 
recent studies have demonstrated that analyzing MPV within 2 hours of sample 
collection have no effects on platelet size. Reference range of MPV in Kilpauk 
Medical College is 6-8.5 fl.  
For my study I am taking the cut- off value of MPV as 8.5 fl. (as per reference 
from previous studies) 
ERYTHROCYTE SEDIMENDATION RATE 
This is the non-specific screening test, that indirectly measures the presence of 
inflammation in the body. It reflects the tendencies of the RBCs to settle more 
rapidly in the face of some diseases because of increase in the plasma 
fibrinogen, immune globulins and acute phase reactants. 
METHODS 
2ml of venous blood is placed in a tube containing anticoagulant citrate or 
EDTA of 0.5ml. The anticoagulated blood shouldn’t  be allowed to stand not 
more than 2 hours in room temperature. The blood is drawn in the Westergrens 
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Katz tube upto 200 mark level. The tube is placed in a rack strictly in a vertical 
position for 1 hour at room temperature, at which time the lowest point of 
surface meniscus to the upper limit of red cell sediment is measured. The 
distance of fall of erythrocytes is measured and it is expressed in millimeters in 
1 hour.  
PARACENTESIS 
PREFERRED  SITE FOR PARACENTESIS 
Left lower quadrant was taken with two finger breadths cephalad and 
two finger breadths medial to the anterior superior iliac spine (RUNYON’S 
SPOT)3,  where the abdominal wall is  thinner with larger pool of fluid. Right 
lower quadrant was not the choice since appendicectomy scar /dilated caecum 
are present. 
 The  Inferior  epigastric arteries  and  midline  (collaterals) were escaped.  
 Visible collaterals were also escaped. 
POSITION OF THE PATIENT 
The head end of the bed elevated . Patients with  large volume of ascites 
and thin abdominal wall were “tapped”  in this supine position. Patients with 
less amount of fluid were placed in the lateral decubitus position and tapped 
from left lower quadrant. 
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NEEDLE OF CHOICE 
Standard   metal   1.5   inch, 22   gauge   needle   is   used,   obese 
Individuals with thick abdominal wall   use longer needle of 3.5 inch length. 
DISINFECTION OF SKIN 6 
As per Universal precautions, gloves  that are sterile were worn for the 
procedure. The skin to be punctured is rubbed using 60% ethanol in a circular 
fashion approximately 4.5cm in diameter and allowed to air dry. Starting at 
the center of the circle, 2% povidone iodine was  applied, until the entire 
circle was saturated with iodine and allowed to dry for one minute. 
TECHNIQUE OF PARACENTESIS 
Under aseptic precautions the disinfected area was injected with local 
anaesthetic, punctured with 22 gauge needle using “Z tract” technique. The 
skin was displaced 2cm downward with one gloved hand. 
Needle  was  introduced through  the abdominal  wall  gently.  The syringe  
with  the  needle  was  aspirated during  insertion. When the needle was  
released, the skin came back to its ground zero position. This helped  the 
needle pathway to be sealed and post-procedural leak was avoided. About 50 
ml of ascitic fluid was withdrawn using syringe. 
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MACROSCOPIC APPEARANCE 
        Colour and appearance of the fluid was noted-whether crystal clear, 
transparent or slightly yellow, cloudy yellow, bloody, opaque and chylous, dark 
brown. 
TRANSPORTNG THE SAMPLES 
15 ml of fluid each was inoculated into 40 ml of Brain Heart Infusion 
(BHI) broth and 40 ml of Thioglycollate broth at the bedside respectively. The 
BHI and the thioglycollate broth bottles were immediately transported to the 
laboratory and incubated at 36°c. Another 4ml was collected in a sterile 
screw capped test tube and sent to the microbiology laboratory . 
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PROCESSING  SAMPLES 
When the test tube was received in the microbiology laboratory, 
conventionally, centrifugation speed was 3000 revolutions/10 minutes and 
centrifuged sample was inoculated into BHI broth in the laboratory, followed up 
and processed along with the BHI broths inoculated at the bedside15. 
MICROSCOPIC EXAMINATION 
From the sediment direct gram stain, acid fast stain was performed. 
BACTERIAL CULTURE 
A part of the sediment was lysed with Triton X-at room temperature,  kept  
5  minutes  and  inoculated  into  Blood  agar,  Mac Conkey agar incubated 
aerobically at 37 °c for 48 hrs, Chocolate agar which incubated at 37 °c in 5% 
CO2 for 48 hrs, Brain heart infusion agar was incubated for 48 hrs. The  broth  
bottles  were  followed for 7  days  with  aerobic  and anaerobic subculturing at 
24, 48 and 168 hrs. Additionally, subculture from bedside BHI broth onto 2% 
Tween 80 BAP was done11. 
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                 CONVENTIONAL BHI VS BEDSIDE BHI 
 
IDENTIFYING ISOLATES 
The preliminary tests-motility, catalase, oxidase Gram stain, were 
performed on all isolates and based on the results further identification of the 
isolates were done by standard microbiological tests. 
ANTIMICROBIAL SUSCEPTIBILITY 
The Isolates subjected to antimicrobial susceptibility testing by Kirby-
Bauer disc diffusion method.  
Mueller-Hinton  agar   (MHA)   plate   is   inoculated   with   0.5 
McFarland  standard of the isolate to get a lawn culture. Using sterile forceps, 
the antibiotic discs were placed over the agar surface, incubated at 37°C in 
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ambient air for 16 to 18 hrs. The results were interpreted as per Clinical 
Laboratory Standards Institute Guidelines (CLSI Guidelines 2012). 
The  Escherichia  coli  ATCC  25922,  Staphylococcus  aureus ATCC 
25923 and Pseudomonas aeruginosa ATCC 27853 were used as quality control 
strains. 
  YELLOW PIGMENTED PSEUDOMONAS 
 
ASCITIC FLUID - CELL COUNT 
About 4 ml of ascitic fluid was placed in a tube containing the 
anticoagulant EDTA  (ethylenediaminetetraacetic acid)  for  cell  count. Cell 
count is  analysed   by manual method. 
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ASCITIC FLUID-BIOCHEMISTRY 
About 5 ml of ascitic fluid was placed in a tube and sent for 
biochemistry to estimate Glucose, Total protein, albumin (routine), amylase 
and lactate dehyrogenase ( in clinically relevant cases).   
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                      OBSERVATION AND RESULTS 
Ascitic fluid was tapped from 75 Decompensated Liver Disease (DCLD) 
patients (44 Out patients and 31  In patients) under aseptic precautions.      
CBC, ESR, LFT, RFT, Ascitic fluid PMN count ,were performed in all 
the patients. 
Bacterial  culture is done for the ascitic fluid samples and  the isolates  
are  identified  by  standard  microbiological  tests. Antimicrobial 
susceptibility testing is done for the significant isolates according to CLSI 
Guidelines 2012. 
Univariate analysis of the data was done by Pearson Chi-Square Test  and  
Fisher’s  Exact  Test.  The  p  values  less  than  0.01  were considered as 
highly stastiscally significant (p <0.01).The p values less than 0.05 were 
considered as stastistically significant (p <0.05) and  Study results are presented 
as follows 
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TABLE 1: DISTRIBUTION OF AGE IN DCLD PATIENT (n=75) 
Age in 
Years 
Outpatients (n=31) Inpatients  (n=44) 
Male Female Male Female 
n=31 % n=0 % n=37 % n=7 % 
30-40 5 16.1 0 0 10 22.7 4 9 
41-50 13 41.9 0 0 4 9 1 2.2 
51-60 11 35.4 0 0 20 45.4 2 4.5 
61-70 2 6.4 0 0 3 6.8 0 0 
 
 
Most of  the DCLD out patients are in the age group of 4 1 - 5 0 yrs, and 
among the in patients, most of them are in the age group of 51-60 yrs. The mean age 
of  all the patients was  49.52 yrs.  The mean age among out patient was 49.03 years. 
The Median age was 50 years. Mean age among inpatients was 49.86 years. Many of 
them are males.  
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TABLE 2: ETIOLOGY AND SEX DISTRIBUTION PATTERN OF DCLD 
PATIENTS: (n=75) 
ETIOLOGY 
Out patients (31) Inpatients (44) 
MALE FEMALE MALE FEMALE 
n=31 % n=0 % n=37 % n=7 % 
Alcohol 24 77.4 0 0 29 65.9 1 2.3 
HBV 3 9.6 0 0 2 4.5 6 13.6 
HCV 0 0 0 0 1 2.3 0 0 
Alcohol+HBV 2 6.4 0 0 1 2.3 0 0 
Alcohol+HCV 1 3.2 0 0 0 0 0 0 
OTHERS 1 3.2 0 0 4 9 0 0 
 
Alcoholic Liver  cirrhosis is the frequent cause of ascites among men in 
outpatient (77.4%) and inpatient (65.9%) category. 
HBV related cirrhosis is the most common cause among the inpatient 
females(85.7%). 
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TABLE 3:  SIGNIFICANT CLINICAL FEATURES IN CIRRHOTIC 
INPATIENTS PRESENTING WITH OR WITHOUT AFI 
SIGNS & SYMPTOMS 
Inpatients n=44 
AFI (n=29) NO AFIs (n=15) 
Abdominal Pain(AP) 1 2 
UGI Bleeding (UGB) 0 4 
Diarrhoea (D) 0 0 
Hepatic Encephalopathy (HE) 1 3 
Fever (F) 6 3 
AP+F+D 2 0 
AP+UGB+F 0 0 
AP+F 17 2 
UGB+F 2 0 
HE+UGI B 0 1 
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Among the patients with ascitic fluid infections, the most common presenting 
symptoms are a combination of Abdominal pain and fever 17 out of 29 (58.6%) 
whereas fever alone is present in 6 out of 29 patients(20.6%). Abdominal pain alone 
is present in 1 out of 29 patients(3.4%). 
TABLE 4: LABORATORY PARAMETERS IN CIRRHOTIC PATIENTS: 
(n=75) 
Laboratory Parameters 
Outpatients 
(n=31) 
Inpatients 
(n=44) 
Total 
(n=75) 
HB (gm%) 
<7 0 0 0 
7-9 18 31 49 
>9 13 13 26 
TC 
(cells/cu.mm) 
<4000 2 0 2 
4000-12000 29 39 68 
>12000 0 5 5 
PLATELETS 
(cells/cu.mm) 
<100000 4 40 44 
≥100000 27 4 31 
MPV(fl) 
<8.5 31 18 49 
>8.5 0 26 26 
ESR ≤30 29 8 37 
(mm/hr) >30 2 36 38 
0
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Inpatients AFI (n=29)
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By comparing the laboratory parameters among inpatient and outpatients, it is 
found from the above table that Total Leucocyte Count (TC) >12000 was found in 5 
out of 44 (11.36%) of patients, whereas 0 out of 44 none of the out patients had 
elevated TC above>12000. 
 
Platelet count is reduced to less than 100000 in 40 out of 44 (91%) among the  
inpatients.  MPV was significantly elevated  to more than 8.5 fl in 26 out of 44 (59%) 
inpatients. In outpatient none of them had an elevated MPV. ESR elevated to more 
than 30 in 36 out of 44 (81.8%) inpatients. Only 2 out of 31(6.4%) outpatients had 
elevated ESR to more than 30.  
TC, Platelet count, MPV and ESR were found to be statistically significant among 
inpatients and outpatients. 
0
10
20
30
40
50
60
70
  <
7
7
 t
o
 9 >
9
<
4
0
0
0
4
0
0
0
-1
2
0
0
0
>
1
2
0
0
0
<
1
0
0
0
0
0
≥1
0
0
0
0
0
 
<
8
.5
>
8
.5
≤3
0
 
>
3
0
HB (gm%) TC (cells/cu.mm)PLATELETS(cells/cu.mm)MPV(fl) ESR(mm/hr)
Outpatients (n=31)
Inpatients (n=44)
Total (n=75)
70 
 
TABLE 5 : LABORATORY PARAMETERS IN CIRRHOTIC PATIENTS 
WITH OR WIHOUT AFI 
Laboratory Parameters 
AFI 
(n=29) 
WIHOUT 
AFI (n=15) 
Total 
(n=44) 
HB (gm%) 
<7 1 2 3 
7-9 18 10 28 
>9 10 3 13 
TC 
(cells/cu.mm) 
<4000 0 0 0 
4000-12000 24 15 39 
>12000 5 0 5 
PLATELETS 
(cells/cu.mm) 
<100000 27 13 40 
≥100000 2 2 4 
MPV 
(fl) 
<8.5 5 13 18 
>8.5 24 2 26 
ESR 
(mm/hr) 
≤30 1 7 8 
>30 28 8 36 
 
The above table compare the laboratory parameters among the patients with or 
without Ascitic fluid infection and found that TC was elevated to more than 12000 in 
5 out of 29 patients(17.2%) with AFI and no patient without AFI had elevated count. 
Platelet count was reduced to 100000 in 27 out of 29 patients (93%) with AFI  
and in 13 out of 15 (86%) patients without AFI  
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MPV was elevated to more than 8.5 in 24 out of 29 (83%)patients with AFI 
and in 2 out of 15 (13.3%) of patients without AFI.  
ESR was elevated to more than 30 in 28 out of 29 (96%) of patients with AFI 
and in 8 out of 15 (53%) patients without AFI. So, TC, MPV and ESR were 
statistically significant among the patients with and without AFI 
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TABLE 6: LABORATORY PARAMETERS  LFT  IN CIRRHOTIC PATIENTS  
(n=75) 
Laboratory Parameters 
Outpatients 
(n=31) 
Inpatients 
(n=44) 
Total (n=75) 
S.BILIRUBIN 
(mg%) 
<3 13 0 13 
>3 18 44 62 
TOTAL 
PROTEIN(gm/dl) 
<6.5 19 44 63 
>6.5 12 0 12 
S.ALBUMIN 
(gm%) 
<3.5 12 39 51 
≥3.5 19 5 24 
AST(U/L) 
<30 10 1 11 
>30 21 43 64 
ALT(U/L) 
<30 24 2 26 
>30 7 42 49 
PT-INR 
≤1.5 25 25 50 
>1.5 6 19 25 
 
The above table compares the parameters of Liver Function Test among the 
inpatient and outpatients, and it is found that Serum Bilirubin was elevated to more 
than 3mg% in 18 out of 31 (58%) outpatient, whereas it is elevated to more than 3 in 
all inpatients 44 out of 44 (100%). 
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Total protein was reduced to less than 6.5gm% in 19 out of 31 (61.2%) 
outpatient, whereas all inpatients had reduced Total Protein 44 out of 44 (100%). S 
albumin reduced to 3.5gm% in 39 out of 44 (88.8%) in inpatients & outpatients 12/31 
(38.7%) 
AST, ALT and PT-INR had no statistically significant correlation from the above 
table. 
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TABLE 7: LABORATORY PARAMETERS  LFT  IN IN PATIENTS  WITH OR 
WITHOUT AFI 
Laboratory Parameters AFI (n=29) 
WITHOUT AFI 
(n=15) 
Total (n=75) 
S.BILIRUBIN 
(mg%) 
<3 0 0 0 
>3 29 15 44 
TOTAL 
PROTEIN(gm/dl) 
<6.5 29 15 44 
>6.5 0 0 0 
S.ALBUMIN 
(gm%) 
<3.5 25 14 39 
≥3.5 4 1 5 
ALT(U/L) 
<30 2 0 2 
>30 27 15 42 
AST(U/L) 
<30 1 0 1 
>30 28 15 43 
PT-INR 
≤1.5 17 8 25 
>1.5 12 7 19 
 
The above table compares the parameters of Liver Function Test among the 
patients with AFI and without AFI, and it is found that Serum Bilirubin was elevated 
to more than 3 in all patients with AFI 29 out of 29 (100%) and without AFI 15 out 
of  15 (100%). Total protein was reduced to less than 6.5gm% in  all patients with 
AFI 29 out of 29 (100%). 
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Serum albumin was reduced to less than 3.5gm% in 25 out of 29 (86.2%) in 
patients with AFI and in 14 out of 15 (93.3%) in patients without AFI. AST, ALT 
and PT-INR had no statistically significant correlation from the above table. 
 
TABLE 8: LABORATORY PARAMETERS  RFT  IN CIRRHOTIC PATIENTS  
(n=75) 
Laboratory Parameters 
Out 
patients 
(n=31) 
In patients 
(n=44) 
Total 
(n=75) 
B.UREA 
(mg%) 
<28 6 20 36 
>28 15 22 37 
S.CREATININE 
(mg%) 
<1 30 35 65 
>1 1 9 10 
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The above table compares the parameters of Renal Function Test among the 
inpatient and outpatients, and it is found that Blood Urea was elevated to more than 
28mg% in 15 out of 31 (48.3%)  outpatient and in 22 out of 44(50%)  inpatient. 
Serum creatinine was elevated to more than 1 mg% in 1 out of 31 (3.2%) outpatient 
and in 9 out of 44 (20.4%)  inpatient. 
 
So, Blood urea and serum creatinine had no statistically significant correlation 
among inpatient and outpatient. 
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TABLE 9: LABORATORY PARAMETERS  RFT  IN IN PATIENTS  WITH OR 
WITHOUT AFI 
Laboratory Parameters 
AFI 
(n=29) 
WITHOUT 
AFI (n=15) 
Total 
(n=75) 
B.UREA 
(mg%) 
<28 13 8 21 
>28 16 7 23 
S.CR 
(gm%) 
<1 24 11 35 
>1 5 4 9 
 
The above table compares the parameters of Renal Function Test among the 
patients with AFI and without AFI, and it is found that Blood Urea was elevated to 
more than 28mg% in 16 out of 29 (55.1%)  patient with AFI and in 7 out of 15 
(46.6%)  patient without AFI. Serum creatinine was elevated to more than 1 mg% in 5 
out of 29 (17.2%) patient with AFI and in 4 out of 15 (26.6%)  patient wihout AFI 
 
So, Blood urea and serum creatinine had no statistically significant correlation 
among the patients wih or without AFI. 
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TABLE 10: COMPARISION BETWEEN ASCITIC FLUID PMN COUNT 
AND CULTURE 
PMN COUNT 
(cells/cu.mm) 
CULTURE 
POSITVE NEGATIVE 
<250 ( n=57) 11 46 
>250 (n=18) 18 0 
 
In the ascitic fluid analysis, 57 patient had Poly Morpho Neutrophil count less than 
250. Out of 57 patients, 11 patients had positive ascitic fluid culture report. 
18 patients had Poly Morpho Neutrophil count more than 250. All the patient having 
PMN count more than 250 had positive ascitic fluid culture positivity. 
 
 Spontaneous Bacterial Peritonitis (SBP) =18 
 Monomicrobial Nonneutrocytic Bacterascites (MNB) =11 
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TABLE 11 : COMPARISON OF BLOOD NEUTROPHIL COUNT VS 
ASCITIC FLUID IN PATIENTS WITH AFIS: 
Ascitic fluid PMN 
count 
AFIs No. of isolates 
Leukocytosis (>11,000) 
with Neutrophils  
>60% 
≥250/mm3 SBP 18 9 
<250/mm
3
 MNB 11 2 
 
 
 
From the above table it is inferred that, out of 18 patients having SBP, 9 had  
leucocyte count more than 11000 with neutrophils more than 60% Out of 11 patients 
having MNB, 2 had leucocyte count more than 11000 with neutrophils more than 60. 
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TABLE 12: ASCITIC FLUID INFECTIONS (AFIS) IN CIRRHOTICS  OF 
VARIED ETIOLOGIES. 
ETIOLOGICAL FACTORS 
CULTURE POSITIVES 
GPC 
n=1 
GNB 
n=28 
TOTAL 
n=29 
Alcohol 1 19 20 
HBV 0 4 4 
HCV 0 1 1 
Alcohol/HBV 0 1 1 
Cryptogenic 0 2 2 
Non Alcoholic Fatty Liver 
Disease 
0 1 1 
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The above table shows that, the most common organism causing ascitic fluid 
infection was gram negative bacilli 28 out of 29 (96.5%). Alcohol is the most 
common risk factor for ascitic fluid infection 20 out of 29 (68.9%) 
TABLE 13: MICROBIAL PROFILE ISOLATED AMONG  INPATIENTS 
WITH DCLD 
PATIENT CATEGORY 
CULTURE 
POSITIVES 
GPC GNB 
INPATIENTS 
(44) 
Males(37) 26 1 25 
Females(7) 3 0 3 
TOTAL 29 1 28 
 
The above table shows that, among the inpatient 37 male, 26 patient had 
AFI. Out of 26 patient, 25 patient had ascitic fluid infection caused by gram 
negative bacilli (96.1%) Out of 7 female inpatient, 3 had  ascitic fluid infection. 
All of them were infected by gram negative bacilli (100%) 
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TABLE 14: CLASSIFICATION OF ASCITIC FLUID INFECTIONS IN 
CIRRHOTICS PATIENTS VARIANTS OF AFIs 
VARIANTS TOTAL 
Culture Positives 
GPC GNB 
Spontaneous bacterial 
peritonitis (SBP) 
18 0 18 
Monomicrobial non-
neutrocytic bacterascites 
11 1 10 
TOTAL 29 1 28 
 
Among the asctic fluid infection in DCLD patients, 18 out of 29(62%) 
had SBP. 11out of 29(37.9%) had MNB. The most common organism was 
gram negative bacilli in both SBP and MNB category. 
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TABLE:15 RELATIONSHIP BETWEEN MPV AND VRIOUS ETIOLOGIES 
OF CIRRHOSIS 
ETIOLOGY 
MPV 
TOTAL P VALUE 
<8.5 >8.5 
ALCOHOL 
YES 39 19 58 
0.927 
NO 10 7 17 
HBV 
YES 9 5 14 
0.522 
NO 40 21 61 
HCV 
YES 2 0 2 
0.296 
NO 47 26 73 
 
From the above table it was inferred that  MPV had no statistically  significant 
correlation with various etiologies of Decompensated Liver Disease. 
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TABLE 16: RELATIONSHIP BETWEEN MPV AND VARIOUS  CLINICAL 
FEATURES 
CLINICAL FEATURES 
MPV 
TOTAL P VALUE 
<8.5 >8.5 
Abdominal pain 
Yes 4 20 24 
0.000 
no 45 6 51 
Fever 
Yes 7 25 32 
0.000 
No 42 1 43 
UGI bleed 
Yes 6 1 7 
0.234 
No 43 25 68 
HE 
Yes 5 0 5 
0.092 
No 44 26 70 
Diarrhea 
Yes 0 2 2 
0.049 
No 49 24 73 
 
The above table shows that MPV was elevated in 20 out of 24 (83.3%) patients 
having abdominal pain with a significant p value of less than 0.005. 
MPV was elevated in 25 out of 32 (78.1%) patients having fever with a 
significant p value of less than 0.005. 
MPV had no statistical significance with UGI bleed, Hepatic Encephalopathy 
and diarrhea. 
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TABLE 17: RELATIONSHIP BETWEEN MPV AND HAEMOGLOBIN 
LAB.VALUES 
MPV (fl) 
TOTAL 
n=75 
P VALUE <8.5 
n=59 
>8.5 
n=26 
Hb(gm%) 
<7 2 1 3 
0.868 7-9 29 17 46 
>9 18 8 26 
 
 
 Out of 75 patients, 46 patients had haemoglobin value between 7 and 10. 
 3 out of 75 had HB less than 7. 
 26 out of 75 had HB more than 7. 
 MPV had no statistically significant correlation with Haemoglobin. 
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TABLE 18: RELATIONSHIP BETWEEN MPV AND TOTAL COUNT 
LAB.VALUES 
MPV (fl) 
TOTAL 
n=75 
P VALUE <8.5 
n=59 
>8.5 
n=26 
TC 
(cells/cu.
mm) 
<4000 4 0 4 
0.001 4000-12000 45 21 66 
>12000 0 5 5 
 
The above table compares the MPV with Total Leucocyte count.  
 Out of 75 patients, 66(88%) had TC between 4000-12000. Out of 66 patients, 
21 had MPV >8.5(31.8%) 
 5 out of 75 patients had had TC more than 12000(6.6%). All 5 patients had 
MPV >8.5(100%) 
 MPV had  statistically significant correlation with total Leucocyte count with a 
P value <0.005 
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TABLE 19:  RELATIONSHIP BETWEEN MPV AND ESR 
LAB.VALUES 
MPV (fl) 
TOTAL 
n=75 
P VALUE 
<8.5  
n=59 
>8.5  
n=26 
ESR 
(mm/hr) 
<=30 37 0 37 
0.001 
>30 12 26 38 
 
The above table compares the MPV with Erythrocyte Sedimentation Rate.  
 Out of 75 patients, 37(49.3%) had ESR less than 30. Out of 37 patients, none 
had MPV >8.5(0%) 
 38 out of 75 patients had  ESR more than 30 (50.6%).  Out of 38 patients, 26 
had MPV >8.5(68.4%) 
 MPV had  statistically significant correlation with Erythrocyte Sedimentation 
Rate  with  a P value <0.005 
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TABLE 20 : RELATIONSHIP BETWEEN MPV AND PLATELETS 
LAB.VALUES 
MPV (fl) 
TOTAL 
n=75 
P VALUE <8.5 
n=59 
>8.5 
n=26 
platelets 
(cell/cu.mm) 
<=100000 20 24 44 
0.000 
>100000 29 2 31 
 
The above table compares the MPV with Platelet count.  
 Out of 75 patients, 44(58.6%) had platelet count <100000.Out of 44 patients, 
20 had MPV <8.5(45.4%) 
 24 out of 44 patients with platelet count <100000  had MPV >8.5(54.5%) 
whereas 2 out of 31 patients with platelet count <100000  had MPV 
>8.5(6.4%) 
 MPV had  statistically significant correlation with Platelet count with a P value 
<0.005 
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TABLE 21: RELATIONSHIP BETWEEN LFT/ RFT AND MPV 
LAB VALUES 
MPV 
Total PVALUE 
<8.5 >8.5 
S.Bilirubin 
<3 13 0 13 
0.002 >3 36 26 62 
TOTAL 59 26 75 
S.Albumin 
<3.5 19 19 38 
0.005 >3.5 30 7 37 
TOTAL 59 26 75 
S.Creatinine 
<1 43 22 65 
0.479 >1 6 4 10 
TOTAL 59 26 75 
 
The above table compares the MPV with S.Bilirubin, S.Albumin and S.Creatinine.  
 Out of 62 patients with S.Bilirubin >3mg%, 26 patients had MPV >8.5(41.9%). 
None with S.Bilirubin < 3mg% had MPV >8.5(0%)  
 Out of 38 patients with S.Albumin <3.5mg%, 19 patients had MPV >8.5(50%).  
 Out of 10 patients with S.Creatinine >1mg%, 4 patients had MPV >8.5(40%).  
 MPV had no statistically significant correlation with S.Bilirubin, S.Albumin, 
S.Creatinine 
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TABLE 22: RELATIONSHIP BETWEEN MPV AND PMN COUNT 
LAB.VALUES 
MPV (fl) 
TOTAL 
n=75 
P VALUE 
<8.5 
n=59 
>8.5 
n=26 
PMN 
(cell/cu.mm) 
<250 48 12 60 
0.000 
>250 1 14 15 
 
 Out of 60 patients with PMN count <250, 12 had MPV>8.5(20%) 
 Out of 15 patients with PMN count >250, 14 had MPV>8.5(93.3%) 
So, MPV was significantly correlated to PMN>250 with a P value of 0.000.  
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TABLE 23: RELATIONSHIP BETWEEN MPV AND CELL CULTURE 
LAB.VALUES 
MPV (fl) 
TOTAL 
n=75 
P VALUE 
<8.5 
n=59 
>8.5 
n=26 
Cell culture 
Growth 5 24 29 
0.000 
No growth 44 2 46 
 
Out of 29 positive ascitic fluid culture, 24 patients had elevated MPV of more than 
8.5(82.7%) Whereas only 2 out of 46 patients with ascitic fluid culture had elevated 
MPV of more than 8.5(4.3%) 
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TABLE 24: RELATIONSHIP BETWEEN PMN / CELL CULTURE AND 
MPV 
PMN Culture 
MPV 
Total P VALUE 
<8.5 >8.5 
<250 
Growth 4 10 14 
0.000 
No Growth 44 2 46 
TOTAL 48 12 60 
>250 
Growth 1 14 15 
No Growth 0 0 0 
TOTAL 1 14 15 
 
The above table shows that, 15 patients had both features of PMN count>250 
cells/cu.mm and positive ascitic fluid culture.  
 Out of these 15 patients, 14 had MPV more than 8.5(93.3%). 14 patients had 
both features of PMN count<250 cells/cu.mm and positive ascitic fluid culture.  
 Out of these 14 patients, 10 had MPV more than 8.5(71.4%). 
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So, MPV had significant correlation with both PMN count and Ascitic fluid 
culture. 
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DISCUSSION 
The present study entitiled “MEAN PLATELET VOLUME AN INDICATOR 
OF ASCITIC FLUID INFECTION IN CIRRHOTIC PATIENTS”  done in 
Government Kilpauk Medical college and hospital was a cross sectional study. This 
study was done in patients attending the outpatient Department and in inpatients with 
DCLD and its complications from March 2014 to September 2014. 
Ascitic fluid infection is the second most common complication in DCLD 
patients with the prevalence rate of 9-12%  following UGI bleed, progressing to 
Hepatorenal syndrome and deaths. UGI bleed itself is an important risk factor the 
development of ascitic fluid infections by disrupting the mucosal barrier. The 
mortality  rate in AFI and its complications ranges from 21-41%. So AFI is one of the 
treatable cause of death in DCLD patients. 
Thorough knowledge regarding the pathogenesis, risk factors, microbiological 
profile and its resistance pattern is necessary to bring down the mortality rate 
associated with AFIs. AFI is diagnosed by ascitic fluid PMN count and culture which 
takes minimum of 3 days to get the culture report. So AFIs should be early identified 
and treated to avoid complications. 
Mean Platelet Volume done early within 2 hours of patient presentation, which 
detects the inflammatory process due to the release of inflammatory markers like 
interleukins and its effects on platelet size. 
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During this study eligible patients with ascites were assessed after appropriate 
investigations. 75 patients were identified with ascites due to cirrhosis among 
inpatients and outpatients. 
Most of the patients in our study population were in the age group of 41-50 
years. Among the inpatients, most of them were in the age group of 51-60 years. The 
Mean age of presentation was 49.52 years. Median age was 50 years. There was a 
good correlation with the mean age in the studies Grunhage et al
5
  who had median 
age of 50 years. Dodammani et al
22 
had the similar median age group, Zahidulla et 
al
71
who had population with the mean age group of 52.5 years. 
 Cirrhosis patients consisted of 68 (90.6%) men and 7 (9.3%) women. The 
most common cause of cirrhosis in male patients was ALCOHOLIC CIRRHOSIS 53 
out of  75 (70.6%), 77.4% among inpatients and 65.9% among the outpatients. This 
correlated well with the study Pazhanivel et al
51
and Grunhage et al
5
  where 
alcoholic cirrhosis was 57.5% and 64.5%. 
All the outpatients were asymptomatic. Among the inpatients, the most 
common presenting symptom was abdominal pain with fever(58.6%) which 
correlated well with the studies Caruntu
28
(32%) and McHutchison
48
(68%) 
In our study Leucocyte count was elevated to more than 12000 in11.36% of 
patients. Study conducted by Todd et al
66
 stated that there was subtle elevation of 
leucocyte count due to hypersplenism which was not correlated with our study. 
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ESR was significantly elevated to more than 30 in 96% of patients with AFI 
which correlated well with the study Suvak et al
70 
90% 
MPV was  significantly elevated to more than 8.5 in 83% 0f patients with AFI 
which correlated well with the study Suvak et al
70 
. TC, ESR, MPV were all 
significantly elevated among the inpatients. 
In our study, serum Bilirubin was elevated to more than 3mg% in 100% of 
patients with AFI and in all inpatients. The importance of this parameter as an 
independent risk factor had been ascertained by various studies Angeloni et al
62
, 
Riberiet et al
 55
 who confirmed this importance in their multivariate analysis. 
Low serum Albumin less than 3.5gm% was found in our study in 93.1% of 
patients with AFI. S.Albumin forms the important factor in assessing CTP score. The 
significance of this parameter as an important risk factor was published in an article 
Erica Horinek
24
 . 
In our study, serum Creatinine was elevated to more than 1mg% in 20.4% in 
inpatients and  17.2% in patients with AFI. Serum Creatinine was found as an 
independent risk factor for mortality in the study conducted by Lubna Kamani et al
44
  
and Anastasiou et al
34
 in their multivariate analysis with a high statistical 
significance of(p=0.0098) 
In our study, among the ascitic fluid infections, spontaneous bacterial peritonitis was 
present in 18 patients and monomicrobial non neutrocytic bacterascites was present in 
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11 patients. This had a good correlation with other studies like Pazhanivel et al
51
and 
Riberiet et al
 55
. 
In our study, out of 18 patients having SBP,   9 patients had elevated Leucocyte count 
more than 11000 with peripheral neutrophilis of 60%. This showed that ascitic fluid 
neutrophil had good correlation with peripheral neutrophils. This observation was not 
correlated with study Angeloni et al
6 2 
 which stated that PMN reaches the peritoneal 
fluid in response to specific stimuli and where there are ongoing local pathogenesis as 
stated by Mainor et al
46
. 
In our study, among organisms that cause ascetic fluid infections, Gram  negative 
bacilli was most common 96.1%. This had a good correlation with other studies 
Riberio et al
55
 where 80% was due to GNB and Rimola et al
5
where 65% was due to 
GNB. All female patients were affected by GNB only. 
In our study, MPV was correlated with various etiologies of cirrhosis. There was no 
statistical correlation even in patients with cirrhosis caused by Hepatitis B and C. 
In our study, MPV had a good correlation with clinical features of abdominal pain 
83.3% with a significant p value of 0.005 and of fever 78.1% with a significant p 
value of 0.005 ,  which states that MPV had been elevated in inflammatory 
conditions. 
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In our study, MPV was elevated in 88% of patients having TC between 4000 and 
12000 % with a significant p value of 0.005. This observation had a good correlation 
with other study Suvak et al
70
 with a p value 0.001. 
In our study, MPV was elevated in 68.4% having elevated ESR of more than 30 with 
a significant p value of 0.001. This observation had no correlation with previous 
study Suvak et al
70
. 
In our study, MPV was elevated in 54.5% of patients having platelet count less than 
100000 with a significant p value of 0.000. 
In our study, MPV was elevated in 93.3% of patients having PMN count more than 
250 cells/cu.mm with a significant p value of 0.000.This observation had good 
correlation with the study conducted by Suvak et al
70
.  
In our study, MPV was elevated in 82.7% of patients with a positive ascitic fluid 
culture with a significant p value of 0.000.This observation had good correlation with 
the study conducted by Suvak et al
70
.  
In our study, MPV was elevated in 93.3% of patients having PMN count more than 
250cells/cu.mm and positive ascitic fluid culture with a significant p value of 0.000. 
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LIMITATIONS 
 Ascitic fluid analysis should be done before starting empirical treatment for 
ascitic fluid infections, as even with first dose antibiotics PMN count will 
reduce to less than 250cells/cu.mm and culture may give false negative report. 
 MPV should be done within 2 hours of blood sample collection, because it may 
give false positive MPV report due to cell swelling. 
 Blood sample should sent with appropriate anticoagulant with appropriate 
dose, because it also gives false positive MPV report due to cell swelling. 
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CONCLUSION 
 The prevalence of ascitic fluid infection among inpatients with DCLD is 65.9% 
 The most common risk factor for the development of ascetic fluid infection 
among the inpatient is Alcoholism with the prevalence of 68.9% 
 Ascitic fluid infection is the most common complication in DCLD patients. If 
untreated, it may lead to serious complications like Hepato renal syndrome and 
finally results in death. So, by   identifying ascitic fluid infection early, we can 
reduce the mortality rate. The diagnostic criteria for ascitic fluid infection 
requires ascitic fluid PMN count and culture, of which ascitic fluid culture will 
take atleast 3 days  to have a  report. So, by  measuring Mean Platelet Volume, 
a cheaper and non invasive method, we can diagnose ascitic fluid infection 
early and treat the patient at the earliest. 
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PROFORMA 
NAME :                                                                          DIAGNOSIS: 
AGE/SEX: 
OCCUPATION: 
ADDRESS: 
DETAILS OF PRESENT ILLNESS: 
ABDOMINAL DISTENTION 
 Duration 
 Course 
ABDOMINAL PAIN 
FEVER 
PEDAL EDEMA 
YELLOW COLOURED URINE AND SCLREA 
ASSOCIATED COMPLAINTS: 
 Decreased urine output 
 Breathlesnsss 
 Altered sensorium 
 Hemetemesis , malena 
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PAST HISTORY: Jaundice, tattooing, Major trauma with blood transfusions . 
FAMILY HISTORY: Jaundice, Hepatocellular  Carcinoma, Cirrhosis. 
PERSONAL HISTORY: Sleep,Diet, Smoking, Alcoholism,Drug abuse, Tobacco 
chewing,Sexual contact,   
GENERAL EXAMINATION: 
- Built & nourishment: 
- Height:                   weight:                     BMI: 
- P/I/CY/CL/LN/PE 
- VITALS- PR.BP,RR,TEMPERATURE 
- Signs of Liver cell failure 
SYSTEMIC EXAMINATION 
Abdomen 
 Inspection   : 
 Palpation     : 
 Percussion   : 
 Auscultation: 
 Cardiovascular system 
 Respiratory system 
 Abdominal system 
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INVESTIGATIONS:  
 CBC – TC- 
            DC- 
            Platelets- 
           Mean platelet volume- 
           ESR- 
 BIOCHEMISTRY:- 
                LFT- T.Proteins 
                         Alb/Glb 
                          S.Bilirubin 
                          AST/ALT 
                          SAP 
                 RFT -B.Urea, 
                          S.Creatinine., 
                          Serum electrolytes( Na, K, Ca) 
 URINE ROUTINE EXAMINATION---sugar,albumin, deposits 
  CHEST X-RAY 
 ASCITIC FLUID ANALYSIS 
                Alb 
                T.Proteins. 
                Cell count PMN 
ASCITIC FLUID CULTURE 
NAME AGE SEX OP/IP ALCOHOL HBV HCV OTHERS ABD.PAIN FEVER UGI BLEED HE DIARRHEA HB(GM%) TC DC ESR PLATELETS MPV S.BILIRUBINAST ALT S.PROTEIN S.ALBUMINS.GLB PT INR S.UREA S.CREATININEAF-PMN AF-CULTURE
RAJI 58 M IP YES NO NO YES NO NO NO NO 9.4 6400 68/30/2 40 78000 8.9 10.2 216 112 6 3.2 2.8 1.2 28 0.8 255 E.COLI
ELUMALAI 60 M IP YES NO NO NO YES NO NO NO 9.2 9000 70/27/3 50 55000 8.6 8.6 200 112 5.6 3.6 2 1.6 32 0.7 244 K.PEUMONIAE
DELHIBABU 53 M IP YES NO NO NO YES NO NO NO 8.9 8900 67/28/5 80 94000 8.9 14 198 94 6.2 3.6 2.1 1.4 24 1 200 E.COLI
MANI 46 M OP YES NO NO NO NO NO NO NO 9.6 3700 70/28/2 10 112000 7.9 4.2 28 24 5.6 3.2 2.4 2 24 0.7 20 NO GROWTH
GUNASEKAR 45 M IP YES YES NO YES YES NO NO NO 8.8 10000 82/18/0 80 54000 8.8 6.8 98 94 6 3.5 2.5 0.9 30 0.9 260 K.PEUMONIAE
MOORTHY 38 M IP YES NO NO NO YES NO NO NO 9 5900 68/30/3 24 62000 8 6.4 168 98 5.5 3.4 2.1 1.4 36 1 40 NO GROWTH
VENKATACHALAM 45 M OP YES NO NO NO NO NO NO NO 9.2 6000 65/33/2  125000 8.2 3 46 28 6.5 3.5 3 0.6 24 0.8 44 NO GROWTH
MALLIKA 46 F IP NO YES NO YES YES NO NO NO 8.9 6600 72/28/0 64 72000 8.6 14 126 98 6 3 3 1.2 26 0.9 250 E.COLI
MARI 53 M IP YES NO NO YES NO NO NO NO 8.8 4500 65/33/2 28 100000 8.2 9 136 88 5.8 3.4 2.4 0.9 28 0.7 22 NO GROWTH
BABU 44 M OP YES NO NO NO NO NO NO NO 8 4200 64/34/2 10 115000 7.9 2.8 98 36 6 3.4 2.6 0.9 32 1 20 NO GROWTH
MARUTHAI 69 M IP YES NO NO NO NO YES NO NO 7 5100 60/38/2 28 94000 8 14 264 198 5.8 3.2 2.6 3 30 1.2 56 NO GROWTH
SADASIVAM 56 M IP YES NO NO NO NO YES YES NO 7.2 4200 72/26/2 32 52000 8.2 9.8 196 94 6 3 3 2.8 28 1.1 50 NO GROWTH
SEKAR 55 M IP NO NO NO CYPTOGENICYES YES NO NO NO 8.4 16000 74/26/0 106 56000 9.2 12 77 98 5.6 3.2 2.4 0.9 39 1.5 400 P.AERUGENOSA
RAMESH 44 M OP YES NO NO NO NO NO NO NO 9 4700 64/36/0 32 124000 8.4 2.4 36 24 6.2 3.2 3 1.3 30 1.2 10 NO GROWTH
PALANIVEL 46 M OP YES YES NO NO NO NO NO NO 8.9 5000 68/30/2 20 123000 8.2 3 28 14 6.4 3.5 2.9 1.6 26 0.8 26 NO GROWTH
GANESAN 62 M OP YES NO NO NO NO NO NO NO 8.6 6400 72/26/2 16 115000 08-Jan 3.8 32 18 6 3.5 2.5 0.9 32 1 22 NO GROWTH
KUMAR 48 M IP YES NO NO YES YES NO NO YES 9 12000 80/18/2 94 58000 8.6 12.4 244 168 5.6 3 2.6 1.4 26 0.8 244 S.AUREUS
ROJA 36 F IP YES NO NO NO NO YES NO NO 7.8 6000 70/27/3 30 48000 8.4 10 176 128 5.8 2.9 3.1 0.6 28 0.9 58 NO GROWTH
ATHIYAPPAN 58 M IP NO NO NO NAFLD YES YES NO NO NO 9.2 12200 82/16/2 110 120000 9.5 5.6 30 28 6.5 3.5 3 1.5 36 1 256 ENTEROCOCCI FAECALS
MARI 60 M IP YES NO NO YES YES NO NO NO 8.2 13000 82/17/1 112 66000 8.6 7 46 28 6.2 3.5 2.7 0.9 30 0.9 262 E.COLI
AHMED ARIF 54 M IP NO YES NO NO NO YES NO NO 8.9 4500 68/30/3 44 94000 8.3 21 332 328 5.5 3 2.5 2.4 40 1.4 44 NO GROWTH
THANGAMANI 39 F IP NO YES NO NO NO NO YES NO 8 6700 70/26/4 88 68000 8.2 14 446 428 6.2 3.5 2.7 1.6 32 0.7 56 NO GROWTH
ARUMUGAM 58 M OP YES NO NO NO NO NO NO NO 9.2 4000 62/38/0 14 136000 8.1 2.6 24 18 6.2 3.8 2.4 0.8 26 0.8 12 NO GROWTH
MARIAPPAN 60 M OP YES NO NO NO NO NO NO NO 9.4 5700 60/38/2 10 150000 8.4 1.8 22 16 6.8 3.8 3 1.1 23 0.8 20 NO GROWTH
ANNAMALAI 54 M OP YES NO YES NO NO NO NO NO 8.1 4400 54/42/6 18 124000 8.3 2 36 28 6.4 3.6 2.8 1.7 36 1 62 NO GROWTH
SENTHILKUMAR 35 M IP YES NO NO YES YES NO NO NO 7.8 12500 70/28/2 96 94000 8.8 8.6 156 112 5.5 3 2.5 1.9 35 1.2 310 K.PNEUMONIAE
THANGAVELU 44 M OP YES NO NO NO NO NO NO NO 8.2 5600 62/38/0 14 156000 8.4 3.2 34 28 6.6 3.5 3.1 1.6 28 0.7 34 NO GROWTH
SUMAN 38 M IP NO NO YES YES YES NO NO NO 8.8 10000 72/24/4 64 98000 8.5 14 224 168 5.8 3 2.8 1.8 32 0.9 265 E.COLI
VADIVEL 57 M OP YES NO NO NO NO NO NO NO 8.9 4300 66/30/4 18 10000 8.2 4 36 32 7 3.9 3.1 0.8 28 0.8 24 NO GROWTH
THANIGACHALAM 59 M IP NO NO NO CYPTOGENICYES YES NO NO NO 9 7900 74/24/2 88 126000 9 8.8 168 189 5.8 2.9 2.1 1.9 30 1 340 P.AERUGINOSA
RAMASAMY 54 M OP NO YES NO NO NO NO NO NO 9.4 4800 58/40/2 14 136000 8.1 4.6 224 128 6 3.5 2.5 0.9 24 0.7 26 NO GROWTH
DINESH 38 M IP YES NO NO YES YES NO NO YES 7.9 9800 80/18/2 88 68000 8.8 14.2 268 210 5.6 2.6 2 1.7 28 0.9 290 K.PNUMONIAE
ELLAPPAN 62 M IP YES NO NO YES YES NO NO NO 9.4 12000 82/16/2 94 55000 8.7 18 112 98 6 3.6 2.4 1.2 26 0.7 265 P.MIRABILIS
MARIMUTHU 55 M IP YES NO NO NO NO NO YES NO 8 5800 66/30/4 24 96000 8.1 16 198 124 5.6 2.9 2.7 1.6 29 0.7 50 NO GROWTH
PARAMASIVAM 48 M OP NO YES NO NO NO NO NO NO 8 4300 56/40/4 46 128000 8 3.2 32 28 7 3.7 2.3 0.7 32 0.8 42 NO GROWTH
THIYAGARAJAN 39 M IP YES NO NO YES YES NO NO NO 8.8 9800 76/24/0 86 100000 8.9 8.4 112 98 6 3.4 2.6 1.1 38 1 250 K.PNEMONIAE
LOGANATHAN 52 M OP YES NO NO NO NO NO NO NO 8.9 4200 62/36/2 22 117000 8.2 4 30 24 6.6 3.7 2.9 1.3 27 0.8 32 NO GROWTH
RAMESH 40 M OP YES NO NO NO NO NO NO NO 9 5100 60/36/4 26 145000 8 2.1 22 18 6.4 3.4 3 1.1 29 0.9 42 NO GROWTH
JOTHI 35 F IP NO YES NO YES YES NO NO NO 9.2 12000 82/18/0 90 88000 9.4 6.8 132 98 5.8 2.9 2.9 1.2 34 1.1 500 P.MIRABILIS
SAMPATH 44 M OP YES NO NO NO NO NO NO NO 9.8 5400 62/38/0 14 123000 8.4 1.8 26 24 6.4 3.8 2.6 0.9 28 0.9 34 NO GROWTH
ILAIYARAJA 39 M IP YES NO NO NO YES YES NO NO 9.7 8400 70/26/4 94 78000 8.5 4.2 88 64 6 3.5 2.6 2.8 32 1.2 240 K.PNEUMONIAE
KATHIRVELU 51 M OP NO YES NO NO NO NO NO NO 8.9 5000 64/30/6 18 148000 8 2 32 28 6.6 3.8 2.8 0.9 29 0.9 46 NO GROWTH
KAMARAJ 53 M IP YES NO NO YES YES NO NO NO 8.6 10000 80/18/2 74 82000 9.2 7.8 138 98 5.9 3 2.9 1.2 28 0.8 356 K.PNEUMONIAE
MOHAN 39 M OP YES NO NO NO NO NO NO NO 9.6 6500 66/32/2 16 146000 8.3 3.2 36 24 6.4 3.4 3 1.4 32 0.8 56 NO GROWTH
SIVAKUMAR 40 M IP YES NO NO NO YES NO NO NO 9.5 9800 76/22/2 40 100000 8.2 5.6 58 46 6 3 3 0.9 24 0.8 86 NO GROWTH
GOVINDHAN 62 M IP NO NO NO MALIGNANCYYES NO NO NO NO 7 5200 60/28/2 38 82000 8.4 12 236 240 5.6 3 2.6 1.5 34 1 48 NO GROWTH
JAYAKUMAR 52 M IP NO YES NO NO NO NO YES NO 9.7 5400 64/28/2 22 98000 8.3 16 238 224 5.8 3.3 2.5 1.6 32 0.9 134 E.COLI
ANAND 39 M IP YES NO NO YES YES NO NO NO 9.6 12000 82/16/2 98 55000 9.1 24 198 126 5.5 3.2 3.3 0.9 28 0.8 476 P.MIRABILIS
TAMILARASU 47 M OP YES NO NO NO NO NO NO NO 9 4200 58/38/4 20 180000 8.3 2 18 12 6.8 4 2.8 1.2 34 1 22 NO GROWTH
KUPPAN 60 M IP YES NO NO YES YES NO NO NO 8.9 9900 78/20/2 88 87000 8.5 9.4 126 88 6 3.6 2.4 0.8 28 0.8 120 E.COLI
NAGARAJ 56 M IP YES NO NO NO NO YES NO NO 9.2 5600 66/30/4 24 64000 8.4 12 126 68 6.2 3.7 2.5 3.2 38 1.2 10 NO GROWTH
CHINNAPONNU 40 F IP NO YES NO YES YES NO NO NO 7.4 9900 78/20/2 68 78000 8.6 18 234 198 5.6 3 2.6 0.6 23 0.8 NO CELLS NO GROWTH
KARTHIKEYAN 36 M OP YES NO NO NO NO NO NO NO 8.8 4300 60/28/2 22 134000 8.3 4 32 30 6.5 3.8 2.7 0.7 30 0.9 18 NO GROWTH
SUBBAIYAH 59 M IP YES NO NO NO YES NO NO NO 8.2 8700 72/28/0 68 112000 8.5 6.6 164 98 6 3.5 2.5 1.3 28 0.8 NO CELLS NO GROWTH
KARUPPANNAN 44 M OP YES NO NO NO NO NO NO NO 9.9 4500 58/40/2 12 98000 8.2 4 42 34 6.2 3.8 2.4 0.8 34 0.9 26 NO GROWTH
SUBRAMANI 53 M IP YES NO NO NO YES NO NO NO 9.3 7600 56/40/4 64 68000 8.5 8.6 156 128 5.6 3.2 2.4 1.4 28 1 120 E.COLI
VELPANDIAN 52 M OP YES NO NO NO NO NO NO NO 8.9 5400 66/30/4 22 150000 8 3.2 32 28 6.8 3.8 3 1.6 24 0.8 34 NO GROWTH
THANGAMMAL 56 F IP NO YES NO NO YES YES NO NO 7 6000 70/28/2 60 76000 8.6 7.8 156 94 5.4 3 2.4 3.6 29 0.9 134 E.COLI
NATARAJAN 48 M OP NO NO NO NAFLD NO NO NO NO NO 9.9 4300 60/28/2 20 123000 8 2.8 22 18 6.9 3.6 3.3 1.9 28 0.7 22 NO GROWTH
MAYILVAGANAM 59 M OP YES NO NO NO NO NO NO NO 9.4 4200 64/32/4 14 156000 8.4 4.2 36 28 6.2 3.6 2.6 0.7 32 0.9 12 NO GROWTH
MANNAR 57 M OP YES NO NO NO NO NO NO NO 8.3 5800 66/32/2 16 142000 8.2 3.8 44 26 6 3.5 2.5 1.3 28 0.8 NO CELLS NO GROWTH
SUDDIN 36 M IP YES NO NO NO YES NO NO NO 8.9 12000 80/18/2 80 54000 8.8 12.8 168 144 5.6 2.8 2.8 1.2 32 0.9 200 P.AERUGENOSA
PERUMAL 60 M IP YES NO NO NO YES NO NO NO 9.8 12000 78/18/4 98 89000 9.8 14.6 188 134 5.8 3 2.8 1.9 24 0.9 256 K.PNEUMONIAE
PICHAI 58 M IP YES NO NO YES YES NO NO NO 9 10000 82/18/0 68 78000 9 9.8 146 88 6 3.5 2.5 2 30 1 198 E.COLI
PERUNDEVI 58 F IP NO YES NO NO NO NO YES NO 7.4 6400 64/36/0 28 128000 8.5 7.8 66 44 5.4 2.9 2.3 1.5 28 0.8 32 NO GROWTH
SRINIVASN 39 M OP YES NO NO NO NO NO NO NO 8.3 4200 56/40/4 12 153000 8.1 4 38 32 6 3.8 2.2 0.9 24 0.9 NO CELLS NO GROWTH
MONSOOR 42 M OP YES NO NO NO NO NO NO NO 9.8 4100 60/36/4 18 154000 8.2 3.2 24 18 6.4 3.6 2.8 1.4 32 1 10 NO GROWTH
RAMALINGAM 48 M IP YES NO NO YES YES NO NO NO 9.1 9000 78/28/2 66 78000 8.9 5.8 108 78 5.8 3 2.8 1.6 28 0.8 56 NO GROWTH
SETHURAMAN 49 M OP YES NO NO NO NO NO NO NO 9.2 4000 66/30/4 20 121000 8.3 3 32 24 6.6 4 2.6 1.1 30 1 12 NO GROWTH
KRIHNAMOORTHY 40 M OP YES YES NO NO NO NO NO NO 9.6 3800 64/36/0 18 98000 8.2 4 40 26 6.8 3.8 3 1 28 0.8 45 NO GROWTH
ARULANANDHAM 39 M IP YES NO NO YES YES NO NO NO 8.3 8700 78/28/4 76 65000 9 12.8 163 138 5.9 3 2.9 0.4 32 0.9 250 P.MIRABILIS
AMMAIAPPAN 57 M OP YES NO NO NO NO NO NO NO 8.9 4100 64/30/6 16 127000 8.4 3.2 44 32 6.9 3.6 3.3 1.5 24 0.8 30 NO GROWTH
CHINNADURAI 62 M OP YES NO NO NO NO NO NO NO 9 4300 66/32/2 22 99000 8.1 4.6 68 56 6 3 3 1.2 30 0.9 32 NO GROWTH
ARULNAMBI 41 M IP YES NO NO NO YES NO NO NO 8.6 7800 80/20/0 68 86000 8.7 12.8 114 98 5.4 2.8 2.6 1.9 24 0.9 200 E.COLI
MANIVEL 56 M IP YES NO NO YES YES NO NO NO 7.6 13000 90/10/0 126 96000 9 10.8 244 146 6 3 3 2 40 1.2 355 K.PNEUMONIAE
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